vincetan的个人主页 - 老虎社区

vincetan

vincetan

暂无个人介绍

IP属地：未知

69关注

26粉丝

0主题

0勋章

2021-08-01

New leadership means it's either a change to bring the company forward, or vice versa. Hope it's the former!

P&G beats quarterly sales estimates, warns of cost pressures

2021-08-01

$UNI-ASIA GROUP LIMITED(CHJ.SI)$ hope it keeps going up!

2021-07-27

Any thoughts on this?

2021-07-27

$UNI-ASIA GROUP LIMITED(CHJ.SI)$ hope it keeps going up!

2021-07-25

Potential growth!

2021-07-20

Too late to enter?

2021-07-18

Recent sharp increase. Will it keep going up?

2021-07-16

Hope it goes up soon

2021-07-13

Worth buying?

2021-07-13

$Tesla Motors(TSLA)$ keep rising!!

2021-07-12

Still worth buying?

2021-07-12

$Tesla Motors(TSLA)$ still not going up as much as I hope. Keep rising, tesla!

2021-07-09

Agree on the well explained part. //@Cedric77: Great article! Well explained on current down turn.

抱歉，原内容已删除

2021-07-08

The irony of how biotech should help better lives versus earning lots of profits is always a debatable question.

3 Biotechs to Avoid Like the Plague in July

2021-07-08

Worth considering?

2021-07-07

$NIO Inc.(NIO)$ hopefully it goes up!

2021-07-07

Worth considering?

2021-07-07

I like how old brands like Campbell soup and Colgate are part of the top 40. Legendary brands! 👍

抱歉，原内容已删除

2021-07-06

The true strength of Amazon isn't solely focused on the leader alone, but the rest of the business. Hopefully it sustains and grows!

抱歉，原内容已删除

2021-07-01

$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$ hopefully it keeps going up!

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3583321276956509","uuid":"3583321276956509","gmtCreate":1620229887588,"gmtModify":1622106306048,"name":"vincetan","pinyin":"vincetan","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":26,"headSize":69,"tweetSize":48,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":802868778,"gmtCreate":1627755422494,"gmtModify":1631884081594,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"New leadership means it's either a change to bring the company forward, or vice versa. Hope it's&nbsp;the former!&nbsp;","listText":"New leadership means it's either a change to bring the company forward, or vice versa. Hope it's&nbsp;the former!&nbsp;","text":"New leadership means it's either a change to bring the company forward, or vice versa. Hope it's the former!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/802868778","repostId":"2155013045","repostType":4,"repost":{"id":"2155013045","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627642860,"share":"https://www.laohu8.com/m/news/2155013045?lang=&edition=full","pubTime":"2021-07-30 19:01","market":"us","language":"en","title":"P&G beats quarterly sales estimates, warns of cost pressures","url":"https://stock-news.laohu8.com/highlight/detail?id=2155013045","media":"Reuters","summary":"July 30 (Reuters) - Procter & Gamble Co reported fourth-quarter sales on Friday that beat analysts' ","content":"<p>July 30 (Reuters) - Procter &amp; Gamble Co&nbsp;reported fourth-quarter sales on Friday that beat analysts' estimates, but warned that rising commodity and freight costs would take a $1.9 billion bite out of its earnings this year.</p>\n<p>The vaccine-aided easing of COVID-19 restrictions in the United States and parts of Europe helped the company post an 11% increase in sales at its beauty segment in the reported quarter, as consumers returning to social events, spent more on personal care products.</p>\n<p>Procter &amp; Gamble said net sales rose 7% to $18.95 billion in the quarter ended June 30, compared with estimates of $18.41 billion, according to IBES data from Refinitiv.</p>\n<p>The company forecast fiscal 2022 core earnings per share to rise between 3% and 6%, and sales to increase in the 2% to 4% range.</p>\n<p>Late on Thursday, the Tide detergent maker named Chief Operating Officer Jon Moeller as its new CEO, replacing David Taylor, who will become executive chairman on Nov. 1.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>P&G beats quarterly sales estimates, warns of cost pressures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nP&G beats quarterly sales estimates, warns of cost pressures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-30 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>July 30 (Reuters) - Procter &amp; Gamble Co&nbsp;reported fourth-quarter sales on Friday that beat analysts' estimates, but warned that rising commodity and freight costs would take a $1.9 billion bite out of its earnings this year.</p>\n<p>The vaccine-aided easing of COVID-19 restrictions in the United States and parts of Europe helped the company post an 11% increase in sales at its beauty segment in the reported quarter, as consumers returning to social events, spent more on personal care products.</p>\n<p>Procter &amp; Gamble said net sales rose 7% to $18.95 billion in the quarter ended June 30, compared with estimates of $18.41 billion, according to IBES data from Refinitiv.</p>\n<p>The company forecast fiscal 2022 core earnings per share to rise between 3% and 6%, and sales to increase in the 2% to 4% range.</p>\n<p>Late on Thursday, the Tide detergent maker named Chief Operating Officer Jon Moeller as its new CEO, replacing David Taylor, who will become executive chairman on Nov. 1.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PG":"宝洁"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155013045","content_text":"July 30 (Reuters) - Procter & Gamble Co reported fourth-quarter sales on Friday that beat analysts' estimates, but warned that rising commodity and freight costs would take a $1.9 billion bite out of its earnings this year.\nThe vaccine-aided easing of COVID-19 restrictions in the United States and parts of Europe helped the company post an 11% increase in sales at its beauty segment in the reported quarter, as consumers returning to social events, spent more on personal care products.\nProcter & Gamble said net sales rose 7% to $18.95 billion in the quarter ended June 30, compared with estimates of $18.41 billion, according to IBES data from Refinitiv.\nThe company forecast fiscal 2022 core earnings per share to rise between 3% and 6%, and sales to increase in the 2% to 4% range.\nLate on Thursday, the Tide detergent maker named Chief Operating Officer Jon Moeller as its new CEO, replacing David Taylor, who will become executive chairman on Nov. 1.","news_type":1},"isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802868411,"gmtCreate":1627755232133,"gmtModify":1631889147563,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHJ.SI\">$UNI-ASIA GROUP LIMITED(CHJ.SI)$</a>&nbsp;hope it keeps going up!&nbsp;","listText":"<a href=\"https://laohu8.com/S/CHJ.SI\">$UNI-ASIA GROUP LIMITED(CHJ.SI)$</a>&nbsp;hope it keeps going up!&nbsp;","text":"$UNI-ASIA GROUP LIMITED(CHJ.SI)$ hope it keeps going up!","images":[{"img":"https://static.tigerbbs.com/0ec2f15aa488c141b26b753ddbdbf561","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/802868411","isVote":1,"tweetType":1,"viewCount":256,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":803068226,"gmtCreate":1627396869965,"gmtModify":1631889147575,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"Any thoughts on this?&nbsp;","listText":"Any thoughts on this?&nbsp;","text":"Any thoughts on this?","images":[{"img":"https://static.tigerbbs.com/9f63c2f274fa9680a97f82037443bdbb","width":"1080","height":"3489"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/803068226","isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":803084987,"gmtCreate":1627396665749,"gmtModify":1631889147589,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHJ.SI\">$UNI-ASIA GROUP LIMITED(CHJ.SI)$</a>&nbsp;hope it keeps going up!&nbsp;","listText":"<a href=\"https://laohu8.com/S/CHJ.SI\">$UNI-ASIA GROUP LIMITED(CHJ.SI)$</a>&nbsp;hope it keeps going up!&nbsp;","text":"$UNI-ASIA GROUP LIMITED(CHJ.SI)$ hope it keeps going up!","images":[{"img":"https://static.tigerbbs.com/7d9e3dce81cf36ca5ea821c5be198114","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/803084987","isVote":1,"tweetType":1,"viewCount":426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":177091029,"gmtCreate":1627163772761,"gmtModify":1631889147600,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"Potential growth!&nbsp;","listText":"Potential growth!&nbsp;","text":"Potential growth!","images":[{"img":"https://static.tigerbbs.com/1f4204e1d2bbddc38c1e39d2aaca6b78","width":"1080","height":"3489"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/177091029","isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":171151724,"gmtCreate":1626723016068,"gmtModify":1631889147616,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"Too late to enter?&nbsp;","listText":"Too late to enter?&nbsp;","text":"Too late to enter?","images":[{"img":"https://static.tigerbbs.com/42219fdf52209378b59da8da9140fbdb","width":"1080","height":"3489"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/171151724","isVote":1,"tweetType":1,"viewCount":260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":179274848,"gmtCreate":1626544274584,"gmtModify":1631889147627,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"Recent sharp increase. Will it keep going up?&nbsp;","listText":"Recent sharp increase. Will it keep going up?&nbsp;","text":"Recent sharp increase. Will it keep going up?","images":[{"img":"https://static.tigerbbs.com/994ed0ff59981c6ffb17b3bbe1d409b6","width":"1080","height":"3489"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179274848","isVote":1,"tweetType":1,"viewCount":359,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":147416764,"gmtCreate":1626381138758,"gmtModify":1631884321251,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"Hope it goes up soon","listText":"Hope it goes up soon","text":"Hope it goes up soon","images":[{"img":"https://static.tigerbbs.com/fac2bbd0bfd13c8dd0676d831b606292","width":"1080","height":"3429"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/147416764","isVote":1,"tweetType":1,"viewCount":143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":145397517,"gmtCreate":1626188961639,"gmtModify":1631889147638,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"Worth buying?&nbsp;","listText":"Worth buying?&nbsp;","text":"Worth buying?","images":[{"img":"https://static.tigerbbs.com/59d40da2cb940f58ab55389df62b6753","width":"1080","height":"3429"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/145397517","isVote":1,"tweetType":1,"viewCount":202,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":142937900,"gmtCreate":1626118116600,"gmtModify":1631889147652,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;keep rising!!&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;keep rising!!&nbsp;","text":"$Tesla Motors(TSLA)$ keep rising!!","images":[{"img":"https://static.tigerbbs.com/6088282f18a37677fc335ad1902c4ee6","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/142937900","isVote":1,"tweetType":1,"viewCount":253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148770307,"gmtCreate":1626033424609,"gmtModify":1631889147666,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"Still worth buying?&nbsp;","listText":"Still worth buying?&nbsp;","text":"Still worth buying?","images":[{"img":"https://static.tigerbbs.com/8e2c3cf2a30f1a0f5abb76e06c4c04cc","width":"1080","height":"3429"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148770307","isVote":1,"tweetType":1,"viewCount":237,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148770097,"gmtCreate":1626032993819,"gmtModify":1631889147676,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;still not going up as much as I hope. Keep rising, tesla!&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;still not going up as much as I hope. Keep rising, tesla!&nbsp;","text":"$Tesla Motors(TSLA)$ still not going up as much as I hope. Keep rising, tesla!","images":[{"img":"https://static.tigerbbs.com/da298c293b298102ce18978879e354d0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148770097","isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":143417632,"gmtCreate":1625808852926,"gmtModify":1631888361155,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"Agree on the well explained part.&nbsp;//<a href=\"https://laohu8.com/U/3575196385895354\">@Cedric77</a>: Great article! Well explained on current down turn.&nbsp;","listText":"Agree on the well explained part.&nbsp;//<a href=\"https://laohu8.com/U/3575196385895354\">@Cedric77</a>: Great article! Well explained on current down turn.&nbsp;","text":"Agree on the well explained part. //@Cedric77: Great article! Well explained on current down turn.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143417632","repostId":"1162204971","repostType":4,"isVote":1,"tweetType":1,"viewCount":122,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149876016,"gmtCreate":1625718310035,"gmtModify":1633938032523,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"The irony of how biotech should help better lives versus earning lots of profits is always a debatable question.&nbsp;","listText":"The irony of how biotech should help better lives versus earning lots of profits is always a debatable question.&nbsp;","text":"The irony of how biotech should help better lives versus earning lots of profits is always a debatable question.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/149876016","repostId":"2149365051","repostType":4,"repost":{"id":"2149365051","pubTimestamp":1625648700,"share":"https://www.laohu8.com/m/news/2149365051?lang=&edition=full","pubTime":"2021-07-07 17:05","market":"us","language":"en","title":"3 Biotechs to Avoid Like the Plague in July","url":"https://stock-news.laohu8.com/highlight/detail?id=2149365051","media":"Motley Fool","summary":"Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.","content":"<p>Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-lifetime pandemic. The sector is not without its risks, however. A few small-cap players using questionable science have sold investors on false dreams of miracle drugs that could become game-changers in their field, and in these cases, that couldn't be further from the truth.&nbsp;</p>\n<p>Avoiding bad investments is just as important as making good ones. So let's look at the dark side of investing in biotech and which companies to stay well away from.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6bccd5c36f3f76148be467937b9b6293\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>1. Cel-Sci</h2>\n<p>Sometimes, <a href=\"https://laohu8.com/S/AONE\">one</a> is dealt a bad hand in life and will need to bluff. However, it's a whole different story to double down on a bluff after <a href=\"https://laohu8.com/S/AONE.U\">one</a>'s cover is blown.&nbsp;</p>\n<p>Take the case of&nbsp;<b>Cel-Sci&nbsp;</b>(NYSEMKT:CVM), a small-cap biotech with a single late-stage immunotherapy candidate (Multikine) for treating head and neck cancer. On June 28, Cel-Sci announced that Multikine failed to achieve the primary endpoint of boosting patient survival by 10% compared to standard-of-care treatments in a decade-long phase 3 trial. As a result, the stock lost 66% of its value within four days, to $8.65.</p>\n<p>It's pretty hard to walk away from a giant bluff when there's just too much in the pot. In a conference call to investors on July 1, CEO Geert Kersten heralded the study as a \"success,\" saying that a cohort of patients who received Multikine plus surgery plus radiotherapy \"met the primary endpoint,\" and that Cel-Sci plans to file for regulatory approval. Later on in the call, chief scientific officer Taylor Eval denied all allegations the company was data-mining the study. On a side note, Kersten said he will \"not be releasing the [full] data to shareholders.\"</p>\n<p>The data that management is referring to is from a subgroup of patients in the Multikine cohort who did not receive chemotherapy in the study. This group of patients survived 14.3% longer after five years than the group who received no Multikine at all -- but that does not mean Multikine works on patients without chemotherapy. It has nothing to do with the study's primary endpoint (which includes both patients who did and did not receive chemotherapy). So the data-mining here is, in fact, pretty evident.</p>\n<p>It's also very easy to see how the drug could have a placebo effect. In clinical trials, Multikine was injected in or around the tumor. In case one was wondering, injecting just about anything into a tumor causes the cancer cells to die off -- partly due to needle damage. Moreover, patients in the 9.5-year study received Multikine for just three weeks and were not treated with the drug if their cancer relapsed. So anything (such as lifestyle choices, receiving other immunotherapies post-relapse, etc.) could have been behind the survival difference in the subgroups.</p>\n<p>Before the results came out (which took over a year), Cel-Sci bagged $31.7 million in cash by selling new stock to retail investors, resulting in heavy losses for shareholders less than three weeks after the deal closed. Overall, given the failure of its flagship candidate, the less than $50 million in assets on its books, and questionable conduct from management, this is definitely a biotech you don't want to be holding anytime soon (if not ever).&nbsp;</p>\n<h2>2. CytoDyn&nbsp;</h2>\n<p><b>CytoDyn</b> (OTC:CYDY) is a biotech known for developing leronlimab, an antibody that failed two phase 3 clinical studies for treating COVID-19. In May, the U.S. Food and Drug Administration (FDA) even released a rare statement saying that the drug did not meet the primary endpoints in these studies.&nbsp;</p>\n<p>In response, CEO Nader Pourhassan has adopted a \"catch me if you can\" type of strategy. In other words, CytoDyn simply moved outside of the FDA's jurisdiction and began commercializing the drug in countries like the Philippines.&nbsp;</p>\n<p>It's perplexing as to why the company would risk its relationship with the FDA like this. Aside from the COVID-19 indication, leronlimab is also under investigation for the treatment of HIV. In one study, leronlimab reduced viral load to negligible levels in 83% of patients with HIV.</p>\n<p>I wouldn't be surprised if the rivalry between Pourhassan and the FDA has gone down to the personal level. Last July, the FDA rejected CytoDyn's Biologic License Application (BLA) filing for leronlimab's approval for treating HIV. But the agency did not ask for another clinical trial; it just wanted additional information about the drug and a meeting with company management. CytoDyn has just begun the process to resubmit its BLA on July 1, almost a year later.</p>\n<p>At the end of the day, biotechs with sketchy science and management woes shouldn't be trading at a $1 billion market cap. Take note that CytoDyn has less than $150 million in total assets, leaving shareholders with little recourse in case of further blunders.&nbsp;</p>\n<h2>3. Northwest Biotherapeutics&nbsp;</h2>\n<p><b>Northwest Biotherapeutics</b>&nbsp;(OTC:NWBO) is a company that closely mirrors Cel-Sci in terms of both its science and stock price. Its management is also even more \"audacious\" than that of the previous companies.&nbsp;</p>\n<p>The company's flagship candidate is an immunotherapy known as DCVax-L, which is under investigation for the treatment of glioblastoma multiforme, the most deadly form of brain cancer. The phase 3 study has been going on since December 2006 (almost 15 years now). It was originally a phase 2 study, but the company \"phase-shifted\" it to 3, citing difficulty in finding patients who are comfortable taking a placebo for the deadly illness.</p>\n<p>The study had numerous red flags from the start. Northwest was supposed to conduct two interim analyses of the trial data starting in December 2013. Yes, you read that right, December of 2013. By August 2014, however, the company had released a statement claiming that \"no interim analysis of efficacy in the Phase III trial [had] been done.\" What's more, the FDA halted the DCVax-L clinical trial in August 2015 before lifting it two years later. To this day, Northwest's management has never explained the reasons behind the trial halt.</p>\n<p>The company did eventually perform the interim analyses in 2017 and 2018, but released the results unblinded. When it comes to deadly diseases with significant unmet needs, clinical trials can be stopped early if the experimental drug meets the primary endpoint for ethical reasons. That did not happen with DCVax-L on both occasions.</p>\n<p>Last October, Northwest finally announced that the trial was coming to its end and that data was to be sent for statistical analysis. It's been more than nine months since the announcement, and no news. But, again, from an ethical endpoint, if DCVax-L was working, it doesn't make sense that Northwest wouldn't release top-line data and rush the drug to approval to save lives.</p>\n<p>Shareholders should be expecting a lot of pain ahead, as the company inexplicably has a market cap of $1.27 billion -- with an unpromising candidate and less than $35 million in total assets. All of this makes Northwest's fate look eerily similar to that of Cel-Sci -- and a stock to stay away from for good.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotechs to Avoid Like the Plague in July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotechs to Avoid Like the Plague in July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 17:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CYDY":"CytoDyn Inc.","CVM":"CEL-SCI Corp","NWBO":"西北生物疗法"},"source_url":"https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2149365051","content_text":"Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-lifetime pandemic. The sector is not without its risks, however. A few small-cap players using questionable science have sold investors on false dreams of miracle drugs that could become game-changers in their field, and in these cases, that couldn't be further from the truth. \nAvoiding bad investments is just as important as making good ones. So let's look at the dark side of investing in biotech and which companies to stay well away from. \nImage source: Getty Images.\n1. Cel-Sci\nSometimes, one is dealt a bad hand in life and will need to bluff. However, it's a whole different story to double down on a bluff after one's cover is blown. \nTake the case of Cel-Sci (NYSEMKT:CVM), a small-cap biotech with a single late-stage immunotherapy candidate (Multikine) for treating head and neck cancer. On June 28, Cel-Sci announced that Multikine failed to achieve the primary endpoint of boosting patient survival by 10% compared to standard-of-care treatments in a decade-long phase 3 trial. As a result, the stock lost 66% of its value within four days, to $8.65.\nIt's pretty hard to walk away from a giant bluff when there's just too much in the pot. In a conference call to investors on July 1, CEO Geert Kersten heralded the study as a \"success,\" saying that a cohort of patients who received Multikine plus surgery plus radiotherapy \"met the primary endpoint,\" and that Cel-Sci plans to file for regulatory approval. Later on in the call, chief scientific officer Taylor Eval denied all allegations the company was data-mining the study. On a side note, Kersten said he will \"not be releasing the [full] data to shareholders.\"\nThe data that management is referring to is from a subgroup of patients in the Multikine cohort who did not receive chemotherapy in the study. This group of patients survived 14.3% longer after five years than the group who received no Multikine at all -- but that does not mean Multikine works on patients without chemotherapy. It has nothing to do with the study's primary endpoint (which includes both patients who did and did not receive chemotherapy). So the data-mining here is, in fact, pretty evident.\nIt's also very easy to see how the drug could have a placebo effect. In clinical trials, Multikine was injected in or around the tumor. In case one was wondering, injecting just about anything into a tumor causes the cancer cells to die off -- partly due to needle damage. Moreover, patients in the 9.5-year study received Multikine for just three weeks and were not treated with the drug if their cancer relapsed. So anything (such as lifestyle choices, receiving other immunotherapies post-relapse, etc.) could have been behind the survival difference in the subgroups.\nBefore the results came out (which took over a year), Cel-Sci bagged $31.7 million in cash by selling new stock to retail investors, resulting in heavy losses for shareholders less than three weeks after the deal closed. Overall, given the failure of its flagship candidate, the less than $50 million in assets on its books, and questionable conduct from management, this is definitely a biotech you don't want to be holding anytime soon (if not ever). \n2. CytoDyn \nCytoDyn (OTC:CYDY) is a biotech known for developing leronlimab, an antibody that failed two phase 3 clinical studies for treating COVID-19. In May, the U.S. Food and Drug Administration (FDA) even released a rare statement saying that the drug did not meet the primary endpoints in these studies. \nIn response, CEO Nader Pourhassan has adopted a \"catch me if you can\" type of strategy. In other words, CytoDyn simply moved outside of the FDA's jurisdiction and began commercializing the drug in countries like the Philippines. \nIt's perplexing as to why the company would risk its relationship with the FDA like this. Aside from the COVID-19 indication, leronlimab is also under investigation for the treatment of HIV. In one study, leronlimab reduced viral load to negligible levels in 83% of patients with HIV.\nI wouldn't be surprised if the rivalry between Pourhassan and the FDA has gone down to the personal level. Last July, the FDA rejected CytoDyn's Biologic License Application (BLA) filing for leronlimab's approval for treating HIV. But the agency did not ask for another clinical trial; it just wanted additional information about the drug and a meeting with company management. CytoDyn has just begun the process to resubmit its BLA on July 1, almost a year later.\nAt the end of the day, biotechs with sketchy science and management woes shouldn't be trading at a $1 billion market cap. Take note that CytoDyn has less than $150 million in total assets, leaving shareholders with little recourse in case of further blunders. \n3. Northwest Biotherapeutics \nNorthwest Biotherapeutics (OTC:NWBO) is a company that closely mirrors Cel-Sci in terms of both its science and stock price. Its management is also even more \"audacious\" than that of the previous companies. \nThe company's flagship candidate is an immunotherapy known as DCVax-L, which is under investigation for the treatment of glioblastoma multiforme, the most deadly form of brain cancer. The phase 3 study has been going on since December 2006 (almost 15 years now). It was originally a phase 2 study, but the company \"phase-shifted\" it to 3, citing difficulty in finding patients who are comfortable taking a placebo for the deadly illness.\nThe study had numerous red flags from the start. Northwest was supposed to conduct two interim analyses of the trial data starting in December 2013. Yes, you read that right, December of 2013. By August 2014, however, the company had released a statement claiming that \"no interim analysis of efficacy in the Phase III trial [had] been done.\" What's more, the FDA halted the DCVax-L clinical trial in August 2015 before lifting it two years later. To this day, Northwest's management has never explained the reasons behind the trial halt.\nThe company did eventually perform the interim analyses in 2017 and 2018, but released the results unblinded. When it comes to deadly diseases with significant unmet needs, clinical trials can be stopped early if the experimental drug meets the primary endpoint for ethical reasons. That did not happen with DCVax-L on both occasions.\nLast October, Northwest finally announced that the trial was coming to its end and that data was to be sent for statistical analysis. It's been more than nine months since the announcement, and no news. But, again, from an ethical endpoint, if DCVax-L was working, it doesn't make sense that Northwest wouldn't release top-line data and rush the drug to approval to save lives.\nShareholders should be expecting a lot of pain ahead, as the company inexplicably has a market cap of $1.27 billion -- with an unpromising candidate and less than $35 million in total assets. All of this makes Northwest's fate look eerily similar to that of Cel-Sci -- and a stock to stay away from for good.","news_type":1},"isVote":1,"tweetType":1,"viewCount":263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149870157,"gmtCreate":1625717974079,"gmtModify":1633938035613,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"Worth considering?&nbsp;","listText":"Worth considering?&nbsp;","text":"Worth considering?","images":[{"img":"https://static.tigerbbs.com/a4952811b9de8517292610e3b0b8b607","width":"1080","height":"3528"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/149870157","isVote":1,"tweetType":1,"viewCount":233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":157552513,"gmtCreate":1625593929532,"gmtModify":1633939268114,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>&nbsp;hopefully it goes up!&nbsp;","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>&nbsp;hopefully it goes up!&nbsp;","text":"$NIO Inc.(NIO)$ hopefully it goes up!","images":[{"img":"https://static.tigerbbs.com/cef51ca97f74045e87b17d141370f007","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/157552513","isVote":1,"tweetType":1,"viewCount":387,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":157552845,"gmtCreate":1625593895787,"gmtModify":1633939268236,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"Worth considering?&nbsp;","listText":"Worth considering?&nbsp;","text":"Worth considering?","images":[{"img":"https://static.tigerbbs.com/eda2526c56441b3a5704779a9ec29d2d","width":"1080","height":"3429"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/157552845","isVote":1,"tweetType":1,"viewCount":110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":157556100,"gmtCreate":1625593693200,"gmtModify":1631889933703,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"I like how old brands like Campbell soup and Colgate are part of the top 40. Legendary brands! 👍","listText":"I like how old brands like Campbell soup and Colgate are part of the top 40. Legendary brands! 👍","text":"I like how old brands like Campbell soup and Colgate are part of the top 40. Legendary brands! 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/157556100","repostId":"2149507863","repostType":4,"isVote":1,"tweetType":1,"viewCount":240,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154877681,"gmtCreate":1625510334443,"gmtModify":1633940144150,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"The true strength&nbsp;of Amazon isn't solely focused on the leader alone, but the rest of the business. Hopefully it sustains and grows!&nbsp;","listText":"The true strength&nbsp;of Amazon isn't solely focused on the leader alone, but the rest of the business. Hopefully it sustains and grows!&nbsp;","text":"The true strength of Amazon isn't solely focused on the leader alone, but the rest of the business. Hopefully it sustains and grows!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154877681","repostId":"1157317474","repostType":4,"isVote":1,"tweetType":1,"viewCount":279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158539514,"gmtCreate":1625154535338,"gmtModify":1631888920994,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583321276956509","idStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JLB.SI\">$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$</a>&nbsp;hopefully it keeps going up!&nbsp;","listText":"<a href=\"https://laohu8.com/S/JLB.SI\">$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$</a>&nbsp;hopefully it keeps going up!&nbsp;","text":"$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$ hopefully it keeps going up!","images":[{"img":"https://static.tigerbbs.com/6c1bd42cf964b85c81960a4e99156b8b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158539514","isVote":1,"tweetType":1,"viewCount":226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":157556100,"gmtCreate":1625593693200,"gmtModify":1631889933703,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"I like how old brands like Campbell soup and Colgate are part of the top 40. Legendary brands! 👍","listText":"I like how old brands like Campbell soup and Colgate are part of the top 40. Legendary brands! 👍","text":"I like how old brands like Campbell soup and Colgate are part of the top 40. Legendary brands! 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/157556100","repostId":"2149507863","repostType":4,"isVote":1,"tweetType":1,"viewCount":240,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150288172,"gmtCreate":1624907534196,"gmtModify":1633947207050,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Good to see exponential stocks, but am also a little cautious when it skyrockets too soon, too much.&nbsp;","listText":"Good to see exponential stocks, but am also a little cautious when it skyrockets too soon, too much.&nbsp;","text":"Good to see exponential stocks, but am also a little cautious when it skyrockets too soon, too much.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/150288172","repostId":"2146002845","repostType":4,"repost":{"id":"2146002845","pubTimestamp":1624866683,"share":"https://www.laohu8.com/m/news/2146002845?lang=&edition=full","pubTime":"2021-06-28 15:51","market":"us","language":"en","title":"These Are 5 of the Fastest-Growing Large-Cap Stocks on the Planet","url":"https://stock-news.laohu8.com/highlight/detail?id=2146002845","media":"Motley Fool","summary":"Sales for these companies should skyrocket between 400% and 1,118% over the next four years.","content":"<p>For more than a decade, growth stocks have been all the rage on Wall Street. Historically low lending rates, dovish monetary policy, and a free-spending Capitol Hill (at least during the pandemic) have allowed fast-growing companies to thrive.</p>\n<p>Typically, it's smaller companies that generate some of the fastest sales growth, while large-cap stocks (those with market caps of at least $10 billion) grow at a more tempered pace. Larger companies are more likely to have time-tested or mature operating models, making it less common that they generate eye-popping revenue growth.</p>\n<p>However, the following large-cap stocks didn't get that memo. Each and every <a href=\"https://laohu8.com/S/AONE\">one</a> of these companies is on track to, at minimum, quintuple their sales over a four-year period, according to Wall Street's consensus revenue estimate for 2024 (or fiscal 2025). You could rightly say that these are five of the fastest-growing large-cap stocks on the planet.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ccad26103b3c97bbb65d0cad160f21b9\" tg-width=\"700\" tg-height=\"489\"><span>Image source: Getty Images.</span></p>\n<h2>Sea Limited: Implied four-year sales growth of 400%</h2>\n<p>Who said companies with market caps in excess of $100 billion can't grow like their smaller competitors? According to analysts, Singapore-based <b>Sea Limited</b> (NYSE:SE) is expected to see its full-year sales skyrocket from $4.39 billion in 2020 to about $21.9 billion in 2024. That works out to a quintupling in full-year revenue in four years.</p>\n<p>Sea's secret sauce (say that three times fast) is that it has three rapidly growing operating segments. For the moment, it's being anchored by its digital gaming operations. The company ended March with close to 649 million active users, 12.3% of which were paying to play. That's well above the industry average, and it's notably higher than the 8.9% of quarterly active users who were paying <a href=\"https://laohu8.com/S/AONE.U\">one</a> year ago.</p>\n<p>However, the superstar for this company is its e-commerce platform, Shopee. It's the top shopping app downloaded in Southeastern Asia, and it's becoming especially popular in Brazil. In the first quarter of 2021, Shopee saw $12.6 billion in gross merchandise value (GMV) purchased. For some context here, Shopee did $10.3 billion in GMV in all of 2018. Both the coronavirus pandemic and the rise of the middle class throughout Southeastern Asia is driving online purchases.</p>\n<p>Lastly, Sea has its rapidly growing digital financial services segment. More than 26 million people were paying for mobile wallet services at the end of March. Since the company targets a number of underbanked emerging markets, this digital financial services segment could be a major long-term growth driver.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Plug Power: Implied four-year sales growth of 404%</h2>\n<p>Companies focused on renewable energy solutions should be among the fastest growing this decade. Over the next four years investors will struggle to find a green-energy stock expanding quicker than hydrogen fuel-cell solutions provider <b>Plug Power</b> (NASDAQ:PLUG). After delivering $337 million in sales in 2020, Plug has guided for $1.7 billion in full-year revenue for 2024. That's a cool 404% increase, if it comes to fruition.</p>\n<p>For the time being, climate change is Plug Power's best friend. Joe Biden winning the presidency last year, coupled with Democrats regaining control of the Senate by the narrowest of margins, gives the current administration an opportunity to pass a clean energy bill. While it's unclear what a final infrastructure bill might look like, it's almost a certainty that clean vehicle solutions, such as those developed by Plug Power, will benefit.</p>\n<p>Additionally, the company secured two joint ventures just days apart in January. First, SK Group took a 10% equity stake in the company, with the duo aiming to introduce hydrogen fuel-cell-powered vehicles and hydrogen refilling stations in South Korea. A few days later, Plug landed a deal with French automaker <b>Renault</b> that'll see the two go after Europe's light commercial vehicle market. Both joint ventures should result in Plug Power's orders catapulting higher.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8db519446ea812ab6b8023df3f60f0c3\" tg-width=\"700\" tg-height=\"393\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: Implied four-year sales growth of 559%</h2>\n<p>The cloud computing space is home to dozens of fast-growing companies, none of which appear to be increasing its sales faster than cloud data-warehousing company <b>Snowflake</b> (NYSE:SNOW). In fiscal 2021, Snowflake's sales grew by 124% to $592 million. But based on Wall Street's consensus for fiscal 2025, it's on track to generate $3.9 billion in revenue. This would represent a four-year increase of 559%.</p>\n<p>What makes Snowflake so special is the company's competitive advantages. For example, it's shunned subscriptions in favor of a pay-as-you-go operating model. Customers pay for the amount of data they store and the number of Snowflake Compute Credits used. This allows the company's clients to keep better tabs on their expenses.</p>\n<p>Also, since Snowflake's solutions are built atop the most popular cloud infrastructure platforms, customers can share data seamlessly, even across competing services.</p>\n<p>Though it's the fastest-growing cloud stock, Snowflake is also one of the priciest. It's currently valued at 67 times projected sales for fiscal 2022 and roughly 19 times estimated sales four years from now. But if the company makes good on its fiscal 2029 outlook of $10 billion in product sales, paying this premium may be well worth it.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/96d1687ba107475c062f0147fa401ff2\" tg-width=\"700\" tg-height=\"375\"><span>The NIO EC6 EV crossover SUV. Image source: NIO.</span></p>\n<h2>NIO: Implied four-year sales growth of 561%</h2>\n<p>Another absolute beast of a growth trend this decade is the rise of electric vehicles (EV). Though <b>Tesla</b>&nbsp;and the U.S. EV market tend to get a lot of attention, the biggest opportunity is actually China. That's why <b>NIO</b> (NYSE:NIO) finds itself as one of the fastest-growing large-cap stocks on the planet. If all goes well, full-year sales can catapult from about $2.5 billion in 2020 to $16.8 billion in 2024. That's a sales increase of approximately 561%.</p>\n<p>Despite a global chip shortage, NIO has shown Wall Street that it can effectively scale its production. After delivering 20,060 vehicles in the first quarter, the company is on pace to deliver between 21,000 and 22,000 EVs in the second quarter. Once global chip supply issues are resolved, NIO will look to boost its annual delivery capacity to around 150,000 EVs.</p>\n<p>For NIO, innovation is extremely important. It's been introducing one new vehicle each year, with the sportier EC6 crossover SUV hitting showrooms last summer. It's quickly become a hit with EV buyers.</p>\n<p>Additionally, NIO introduced a battery-as-a-service program. For a monthly fee, this subscription service allows buyers to replace or upgrade their vehicle's batteries. It also reduces the initial purchase price of the vehicle. Though NIO is giving up near-term margin by reducing the purchase price of its EVs, it's keeping buyers loyal and generating very high margin residual service revenue.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/849b25e21ebbcd8fae1e28f0543300db\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Novavax: Implied four-year sales growth of 1,118%</h2>\n<p>The crème de la crème of fast-growing large-cap companies is biotech stock <b>Novavax</b> (NASDAQ:NVAX). Following a pandemic-ravaged year where it brought in $476 million in sales, Wall Street is looking for Novavax to generate $5.8 billion in annual revenue in 2024. That's your run-of-the-mill sales increase of 1,118% over the coming four years.</p>\n<p>As you may have rightly guessed, Novavax's core catalyst is a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, NVX-CoV2373 (these scientific names just roll off the tongue), demonstrated nearly 90% efficacy in a large U.K. study, and recently reported a 90.4% trial efficacy in the United States.&nbsp; With efficacy rates this high, Novavax could potentially displace <b>Johnson &amp; Johnson</b>'s single-dose vaccine, which offered an efficacy of 72%.</p>\n<p>Though you'd think this was a cut-and-dried success story, Novavax has delayed its emergency-use authorization filings in Europe, the U.S., and U.K. until the third quarter, and it likely won't be at full production capacity till the fourth quarter. This waiting game has caused wild vacillations in Novavax's share price of late.</p>\n<p>Nevertheless, Novavax has a good chance of being one of the primary COVID-19 vaccines used in emerging markets, and it could become a key player if booster shots become necessary.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Are 5 of the Fastest-Growing Large-Cap Stocks on the Planet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Are 5 of the Fastest-Growing Large-Cap Stocks on the Planet\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 15:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/27/5-of-fastest-growing-large-cap-stocks-on-planet/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For more than a decade, growth stocks have been all the rage on Wall Street. Historically low lending rates, dovish monetary policy, and a free-spending Capitol Hill (at least during the pandemic) ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/27/5-of-fastest-growing-large-cap-stocks-on-planet/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLUG":"普拉格能源","NIO":"蔚来","NVAX":"诺瓦瓦克斯医药","SE":"Sea Ltd","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/27/5-of-fastest-growing-large-cap-stocks-on-planet/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146002845","content_text":"For more than a decade, growth stocks have been all the rage on Wall Street. Historically low lending rates, dovish monetary policy, and a free-spending Capitol Hill (at least during the pandemic) have allowed fast-growing companies to thrive.\nTypically, it's smaller companies that generate some of the fastest sales growth, while large-cap stocks (those with market caps of at least $10 billion) grow at a more tempered pace. Larger companies are more likely to have time-tested or mature operating models, making it less common that they generate eye-popping revenue growth.\nHowever, the following large-cap stocks didn't get that memo. Each and every one of these companies is on track to, at minimum, quintuple their sales over a four-year period, according to Wall Street's consensus revenue estimate for 2024 (or fiscal 2025). You could rightly say that these are five of the fastest-growing large-cap stocks on the planet.\nImage source: Getty Images.\nSea Limited: Implied four-year sales growth of 400%\nWho said companies with market caps in excess of $100 billion can't grow like their smaller competitors? According to analysts, Singapore-based Sea Limited (NYSE:SE) is expected to see its full-year sales skyrocket from $4.39 billion in 2020 to about $21.9 billion in 2024. That works out to a quintupling in full-year revenue in four years.\nSea's secret sauce (say that three times fast) is that it has three rapidly growing operating segments. For the moment, it's being anchored by its digital gaming operations. The company ended March with close to 649 million active users, 12.3% of which were paying to play. That's well above the industry average, and it's notably higher than the 8.9% of quarterly active users who were paying one year ago.\nHowever, the superstar for this company is its e-commerce platform, Shopee. It's the top shopping app downloaded in Southeastern Asia, and it's becoming especially popular in Brazil. In the first quarter of 2021, Shopee saw $12.6 billion in gross merchandise value (GMV) purchased. For some context here, Shopee did $10.3 billion in GMV in all of 2018. Both the coronavirus pandemic and the rise of the middle class throughout Southeastern Asia is driving online purchases.\nLastly, Sea has its rapidly growing digital financial services segment. More than 26 million people were paying for mobile wallet services at the end of March. Since the company targets a number of underbanked emerging markets, this digital financial services segment could be a major long-term growth driver.\nImage source: Getty Images.\nPlug Power: Implied four-year sales growth of 404%\nCompanies focused on renewable energy solutions should be among the fastest growing this decade. Over the next four years investors will struggle to find a green-energy stock expanding quicker than hydrogen fuel-cell solutions provider Plug Power (NASDAQ:PLUG). After delivering $337 million in sales in 2020, Plug has guided for $1.7 billion in full-year revenue for 2024. That's a cool 404% increase, if it comes to fruition.\nFor the time being, climate change is Plug Power's best friend. Joe Biden winning the presidency last year, coupled with Democrats regaining control of the Senate by the narrowest of margins, gives the current administration an opportunity to pass a clean energy bill. While it's unclear what a final infrastructure bill might look like, it's almost a certainty that clean vehicle solutions, such as those developed by Plug Power, will benefit.\nAdditionally, the company secured two joint ventures just days apart in January. First, SK Group took a 10% equity stake in the company, with the duo aiming to introduce hydrogen fuel-cell-powered vehicles and hydrogen refilling stations in South Korea. A few days later, Plug landed a deal with French automaker Renault that'll see the two go after Europe's light commercial vehicle market. Both joint ventures should result in Plug Power's orders catapulting higher.\nImage source: Getty Images.\nSnowflake: Implied four-year sales growth of 559%\nThe cloud computing space is home to dozens of fast-growing companies, none of which appear to be increasing its sales faster than cloud data-warehousing company Snowflake (NYSE:SNOW). In fiscal 2021, Snowflake's sales grew by 124% to $592 million. But based on Wall Street's consensus for fiscal 2025, it's on track to generate $3.9 billion in revenue. This would represent a four-year increase of 559%.\nWhat makes Snowflake so special is the company's competitive advantages. For example, it's shunned subscriptions in favor of a pay-as-you-go operating model. Customers pay for the amount of data they store and the number of Snowflake Compute Credits used. This allows the company's clients to keep better tabs on their expenses.\nAlso, since Snowflake's solutions are built atop the most popular cloud infrastructure platforms, customers can share data seamlessly, even across competing services.\nThough it's the fastest-growing cloud stock, Snowflake is also one of the priciest. It's currently valued at 67 times projected sales for fiscal 2022 and roughly 19 times estimated sales four years from now. But if the company makes good on its fiscal 2029 outlook of $10 billion in product sales, paying this premium may be well worth it.\nThe NIO EC6 EV crossover SUV. Image source: NIO.\nNIO: Implied four-year sales growth of 561%\nAnother absolute beast of a growth trend this decade is the rise of electric vehicles (EV). Though Tesla and the U.S. EV market tend to get a lot of attention, the biggest opportunity is actually China. That's why NIO (NYSE:NIO) finds itself as one of the fastest-growing large-cap stocks on the planet. If all goes well, full-year sales can catapult from about $2.5 billion in 2020 to $16.8 billion in 2024. That's a sales increase of approximately 561%.\nDespite a global chip shortage, NIO has shown Wall Street that it can effectively scale its production. After delivering 20,060 vehicles in the first quarter, the company is on pace to deliver between 21,000 and 22,000 EVs in the second quarter. Once global chip supply issues are resolved, NIO will look to boost its annual delivery capacity to around 150,000 EVs.\nFor NIO, innovation is extremely important. It's been introducing one new vehicle each year, with the sportier EC6 crossover SUV hitting showrooms last summer. It's quickly become a hit with EV buyers.\nAdditionally, NIO introduced a battery-as-a-service program. For a monthly fee, this subscription service allows buyers to replace or upgrade their vehicle's batteries. It also reduces the initial purchase price of the vehicle. Though NIO is giving up near-term margin by reducing the purchase price of its EVs, it's keeping buyers loyal and generating very high margin residual service revenue.\nImage source: Getty Images.\nNovavax: Implied four-year sales growth of 1,118%\nThe crème de la crème of fast-growing large-cap companies is biotech stock Novavax (NASDAQ:NVAX). Following a pandemic-ravaged year where it brought in $476 million in sales, Wall Street is looking for Novavax to generate $5.8 billion in annual revenue in 2024. That's your run-of-the-mill sales increase of 1,118% over the coming four years.\nAs you may have rightly guessed, Novavax's core catalyst is a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, NVX-CoV2373 (these scientific names just roll off the tongue), demonstrated nearly 90% efficacy in a large U.K. study, and recently reported a 90.4% trial efficacy in the United States.  With efficacy rates this high, Novavax could potentially displace Johnson & Johnson's single-dose vaccine, which offered an efficacy of 72%.\nThough you'd think this was a cut-and-dried success story, Novavax has delayed its emergency-use authorization filings in Europe, the U.S., and U.K. until the third quarter, and it likely won't be at full production capacity till the fourth quarter. This waiting game has caused wild vacillations in Novavax's share price of late.\nNevertheless, Novavax has a good chance of being one of the primary COVID-19 vaccines used in emerging markets, and it could become a key player if booster shots become necessary.","news_type":1},"isVote":1,"tweetType":1,"viewCount":221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":157552513,"gmtCreate":1625593929532,"gmtModify":1633939268114,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>&nbsp;hopefully it goes up!&nbsp;","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>&nbsp;hopefully it goes up!&nbsp;","text":"$NIO Inc.(NIO)$ hopefully it goes up!","images":[{"img":"https://static.tigerbbs.com/cef51ca97f74045e87b17d141370f007","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/157552513","isVote":1,"tweetType":1,"viewCount":387,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":165620137,"gmtCreate":1624131400129,"gmtModify":1634010459395,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Hopefully travel picks up soon!&nbsp;","listText":"Hopefully travel picks up soon!&nbsp;","text":"Hopefully travel picks up soon!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/165620137","repostId":"2144086770","repostType":4,"repost":{"id":"2144086770","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624062134,"share":"https://www.laohu8.com/m/news/2144086770?lang=&edition=full","pubTime":"2021-06-19 08:22","market":"us","language":"en","title":"Largest Boeing 737 MAX model takes off on maiden flight","url":"https://stock-news.laohu8.com/highlight/detail?id=2144086770","media":"Reuters","summary":"RENTON, Wash., June 18 (Reuters) - Boeing Co's 737 MAX 10, the largest member of its best-selling si","content":"<p>RENTON, Wash., June 18 (Reuters) - Boeing Co's 737 MAX 10, the largest member of its best-selling single-aisle airplane family, took off on its maiden flight on Friday, in a further step toward recovering from the safety grounding of a smaller model.</p>\n<p>The plane completed a roughly 2-1/2-hour flight over Washington State, returning to Renton Municipal Airport near Seattle at 12:38 p.m.</p>\n<p>The first flight heralds months of testing and safety certification work before the jet is expected to enter service in 2023.</p>\n<p>In an unusual departure from the PR buzz surrounding first flights, the event was kept low-key as Boeing tries to navigate overlapping crises caused by a 20-month grounding in the wake of two crashes and the COVID-19 pandemic.</p>\n<p>Boeing's 230-seat 737-10 is designed to close the gap between its 178-to-220-seat 737-9, and Airbus's 185-to-240-seat A321neo, which dominates the top end of the narrowbody jet market, worth some $3.5 trillion over 20 years.</p>\n<p>However, the market opportunity for the 737 MAX 10 is constrained by the jet's range of about 3,300 nautical miles (6,100 km), which falls short of the A321neo's roughly 4,000 nm.</p>\n<p>Boeing must also complete safety certification of the plane under a tougher regulatory climate following two fatal crashes of a smaller 737 MAX version grounded the model for nearly two years - with a safety ban still in place in China.</p>\n<p>Boeing has carried out design and training changes on the MAX family, which returned to U.S. operations in December.</p>\n<p>Boeing Commercial Airplanes CEO Stan Deal said the company is producing about 16 737 MAX jets a month at its Renton factory.</p>\n<p>Boeing is working on safety enhancements for the 737 MAX 10, including for its air data indication system and adding a third cockpit indication requested by European regulators of the \"angle of attack,\" a parameter needed to avoid stalling or losing lift. Deal’s comments were provided to the media via a pool reporter inside a Boeing aircraft delivery center.</p>\n<p>\"We're going to take our time on this certification,\" Deal said.</p>\n<p>While the smaller MAX 8 is Boeing's fastest-selling jet, slow sales of the MAX 9 and 10 models have put Boeing at a disadvantage to the A321neo.</p>\n<p>Boeing has abandoned plans to tinker with the 737 MAX 10 design, but is weighing a bolder plan to replace the single-aisle 757, which overlaps with the top end of the MAX family.</p>\n<p>Even so, Boeing says it is confident in the MAX 10, and it is stepping up efforts to sell more of the jet, with key targets, including Ireland's Ryanair .</p>\n<p>Customers include United Airlines with 100 on order. Although sources say United is weighing a new order for at least 100 or even up to 200 MAX, its requirement for large single-aisles will be served by Airbus - reinforcing the market split.</p>\n<p>The flight, watched by dozens of employees but virtually no visitors as Boeing sought to downplay the event, showcased a revamped landing gear system illustrating an industry battle to squeeze as much mileage as possible out of the current generation of single-aisles.</p>\n<p>It raises the landing gear's height during take-off and landing, a design needed to compensate for the MAX 10's extra length and prevent the tail scraping the runway on take-off.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Largest Boeing 737 MAX model takes off on maiden flight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLargest Boeing 737 MAX model takes off on maiden flight\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-19 08:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>RENTON, Wash., June 18 (Reuters) - Boeing Co's 737 MAX 10, the largest member of its best-selling single-aisle airplane family, took off on its maiden flight on Friday, in a further step toward recovering from the safety grounding of a smaller model.</p>\n<p>The plane completed a roughly 2-1/2-hour flight over Washington State, returning to Renton Municipal Airport near Seattle at 12:38 p.m.</p>\n<p>The first flight heralds months of testing and safety certification work before the jet is expected to enter service in 2023.</p>\n<p>In an unusual departure from the PR buzz surrounding first flights, the event was kept low-key as Boeing tries to navigate overlapping crises caused by a 20-month grounding in the wake of two crashes and the COVID-19 pandemic.</p>\n<p>Boeing's 230-seat 737-10 is designed to close the gap between its 178-to-220-seat 737-9, and Airbus's 185-to-240-seat A321neo, which dominates the top end of the narrowbody jet market, worth some $3.5 trillion over 20 years.</p>\n<p>However, the market opportunity for the 737 MAX 10 is constrained by the jet's range of about 3,300 nautical miles (6,100 km), which falls short of the A321neo's roughly 4,000 nm.</p>\n<p>Boeing must also complete safety certification of the plane under a tougher regulatory climate following two fatal crashes of a smaller 737 MAX version grounded the model for nearly two years - with a safety ban still in place in China.</p>\n<p>Boeing has carried out design and training changes on the MAX family, which returned to U.S. operations in December.</p>\n<p>Boeing Commercial Airplanes CEO Stan Deal said the company is producing about 16 737 MAX jets a month at its Renton factory.</p>\n<p>Boeing is working on safety enhancements for the 737 MAX 10, including for its air data indication system and adding a third cockpit indication requested by European regulators of the \"angle of attack,\" a parameter needed to avoid stalling or losing lift. Deal’s comments were provided to the media via a pool reporter inside a Boeing aircraft delivery center.</p>\n<p>\"We're going to take our time on this certification,\" Deal said.</p>\n<p>While the smaller MAX 8 is Boeing's fastest-selling jet, slow sales of the MAX 9 and 10 models have put Boeing at a disadvantage to the A321neo.</p>\n<p>Boeing has abandoned plans to tinker with the 737 MAX 10 design, but is weighing a bolder plan to replace the single-aisle 757, which overlaps with the top end of the MAX family.</p>\n<p>Even so, Boeing says it is confident in the MAX 10, and it is stepping up efforts to sell more of the jet, with key targets, including Ireland's Ryanair .</p>\n<p>Customers include United Airlines with 100 on order. Although sources say United is weighing a new order for at least 100 or even up to 200 MAX, its requirement for large single-aisles will be served by Airbus - reinforcing the market split.</p>\n<p>The flight, watched by dozens of employees but virtually no visitors as Boeing sought to downplay the event, showcased a revamped landing gear system illustrating an industry battle to squeeze as much mileage as possible out of the current generation of single-aisles.</p>\n<p>It raises the landing gear's height during take-off and landing, a design needed to compensate for the MAX 10's extra length and prevent the tail scraping the runway on take-off.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BA":"波音"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144086770","content_text":"RENTON, Wash., June 18 (Reuters) - Boeing Co's 737 MAX 10, the largest member of its best-selling single-aisle airplane family, took off on its maiden flight on Friday, in a further step toward recovering from the safety grounding of a smaller model.\nThe plane completed a roughly 2-1/2-hour flight over Washington State, returning to Renton Municipal Airport near Seattle at 12:38 p.m.\nThe first flight heralds months of testing and safety certification work before the jet is expected to enter service in 2023.\nIn an unusual departure from the PR buzz surrounding first flights, the event was kept low-key as Boeing tries to navigate overlapping crises caused by a 20-month grounding in the wake of two crashes and the COVID-19 pandemic.\nBoeing's 230-seat 737-10 is designed to close the gap between its 178-to-220-seat 737-9, and Airbus's 185-to-240-seat A321neo, which dominates the top end of the narrowbody jet market, worth some $3.5 trillion over 20 years.\nHowever, the market opportunity for the 737 MAX 10 is constrained by the jet's range of about 3,300 nautical miles (6,100 km), which falls short of the A321neo's roughly 4,000 nm.\nBoeing must also complete safety certification of the plane under a tougher regulatory climate following two fatal crashes of a smaller 737 MAX version grounded the model for nearly two years - with a safety ban still in place in China.\nBoeing has carried out design and training changes on the MAX family, which returned to U.S. operations in December.\nBoeing Commercial Airplanes CEO Stan Deal said the company is producing about 16 737 MAX jets a month at its Renton factory.\nBoeing is working on safety enhancements for the 737 MAX 10, including for its air data indication system and adding a third cockpit indication requested by European regulators of the \"angle of attack,\" a parameter needed to avoid stalling or losing lift. Deal’s comments were provided to the media via a pool reporter inside a Boeing aircraft delivery center.\n\"We're going to take our time on this certification,\" Deal said.\nWhile the smaller MAX 8 is Boeing's fastest-selling jet, slow sales of the MAX 9 and 10 models have put Boeing at a disadvantage to the A321neo.\nBoeing has abandoned plans to tinker with the 737 MAX 10 design, but is weighing a bolder plan to replace the single-aisle 757, which overlaps with the top end of the MAX family.\nEven so, Boeing says it is confident in the MAX 10, and it is stepping up efforts to sell more of the jet, with key targets, including Ireland's Ryanair .\nCustomers include United Airlines with 100 on order. Although sources say United is weighing a new order for at least 100 or even up to 200 MAX, its requirement for large single-aisles will be served by Airbus - reinforcing the market split.\nThe flight, watched by dozens of employees but virtually no visitors as Boeing sought to downplay the event, showcased a revamped landing gear system illustrating an industry battle to squeeze as much mileage as possible out of the current generation of single-aisles.\nIt raises the landing gear's height during take-off and landing, a design needed to compensate for the MAX 10's extra length and prevent the tail scraping the runway on take-off.","news_type":1},"isVote":1,"tweetType":1,"viewCount":144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142937900,"gmtCreate":1626118116600,"gmtModify":1631889147652,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;keep rising!!&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;keep rising!!&nbsp;","text":"$Tesla Motors(TSLA)$ keep rising!!","images":[{"img":"https://static.tigerbbs.com/6088282f18a37677fc335ad1902c4ee6","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/142937900","isVote":1,"tweetType":1,"viewCount":253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":127922002,"gmtCreate":1624825493706,"gmtModify":1633948391450,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Reputable stocks worth considering!&nbsp;","listText":"Reputable stocks worth considering!&nbsp;","text":"Reputable stocks worth considering!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/127922002","repostId":"2146090006","repostType":4,"repost":{"id":"2146090006","pubTimestamp":1624755315,"share":"https://www.laohu8.com/m/news/2146090006?lang=&edition=full","pubTime":"2021-06-27 08:55","market":"us","language":"en","title":"5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2146090006","media":"Motley Fool","summary":"These growth and value stocks are begging to be bought by investors.","content":"<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.</p>\n<p>Although Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1077c8372814d2b8150e933b4c608005\" tg-width=\"700\" tg-height=\"466\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>Even though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in <b>Amazon</b> (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.</p>\n<p>As most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.</p>\n<p>But it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Pharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>One reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with <b>Pfizer</b>, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.</p>\n<p>Another reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b152e369d7c967dcbc926192ee888c1\" tg-width=\"700\" tg-height=\"531\"><span>Image source: Getty Images.</span></p>\n<h2>Mastercard</h2>\n<p>Everyone seems to be looking for the smartest recovery play from the pandemic. Payment processor <b>Mastercard</b> (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.</p>\n<p>Mastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.</p>\n<p>Investors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e4e1a1fe028efa4c966b66ef2cd466f5\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>If you have an appetite for turnaround plays, brand-name and generic-drug developer <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.</p>\n<p>While there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.</p>\n<p>Schultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/44a30c4dfd6886a29e22d3c6558c3e56\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>Lastly, bank stock <b>Bank of America</b> (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.</p>\n<p>For much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.</p>\n<p>At the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-27 08:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝","BRK.A":"伯克希尔","AMZN":"亚马逊","TEVA":"梯瓦制药","BRK.B":"伯克希尔B","BAC":"美国银行","MA":"万事达"},"source_url":"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146090006","content_text":"When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.\nAlthough Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nEven though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in Amazon (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.\nAs most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.\nBut it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.\nImage source: Getty Images.\nBristol Myers Squibb\nPharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than Bristol Myers Squibb (NYSE:BMY).\nOne reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with Pfizer, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.\nAnother reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.\nImage source: Getty Images.\nMastercard\nEveryone seems to be looking for the smartest recovery play from the pandemic. Payment processor Mastercard (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.\nMastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.\nInvestors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nIf you have an appetite for turnaround plays, brand-name and generic-drug developer Teva Pharmaceutical Industries (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.\nWhile there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.\nSchultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.\nImage source: Getty Images.\nBank of America\nLastly, bank stock Bank of America (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.\nFor much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.\nAt the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.","news_type":1},"isVote":1,"tweetType":1,"viewCount":280,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159706623,"gmtCreate":1624978883562,"gmtModify":1633946230820,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Besides these 2, are there more stocks to consider?&nbsp;","listText":"Besides these 2, are there more stocks to consider?&nbsp;","text":"Besides these 2, are there more stocks to consider?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/159706623","repostId":"2146388793","repostType":4,"repost":{"id":"2146388793","pubTimestamp":1624959775,"share":"https://www.laohu8.com/m/news/2146388793?lang=&edition=full","pubTime":"2021-06-29 17:42","market":"us","language":"en","title":"2 Robinhood Stocks That Could Crush Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2146388793","media":"Motley Fool","summary":"They're already big winners but could have much more room to run.","content":"<p><b>Dogecoin</b> (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.</p>\n<p>On the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.</p>\n<p>Regardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/21859b0af15cb96a0c3a3aa3d6358251\" tg-width=\"700\" tg-height=\"420\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>NVIDIA</h2>\n<p>While Dogecoin has nosedived in recent months, <b>NVIDIA</b> (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-<a href=\"https://laohu8.com/S/AONE\">one</a> stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.</p>\n<p>However, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.</p>\n<p>Gaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.</p>\n<p>It isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).</p>\n<p>I especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).</p>\n<p>NVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.</p>\n<p>Don't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).</p>\n<p>Assuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.</p>\n<p>Sure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.</p>\n<h2>Moderna</h2>\n<p>Most companies can't honestly say that they've helped change the world.&nbsp;<b>Moderna</b> (NASDAQ:MRNA) can.</p>\n<p>The biotech's COVID-19 vaccine was second only to the vaccine developed by <b>Pfizer</b>&nbsp;and <b>BioNTech</b> to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.</p>\n<p>Based on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.</p>\n<p>In just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.</p>\n<p>But does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.</p>\n<p>The big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.</p>\n<p>Then there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.</p>\n<p>Moderna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.</p>\n<p>All of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Robinhood Stocks That Could Crush Dogecoin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Robinhood Stocks That Could Crush Dogecoin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/06/28/2-robinhood-stocks-that-could-crush-dogecoin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146388793","content_text":"Dogecoin (CRYPTO:DOGE) fans would be quick to point out that the cryptocurrency has skyrocketed more than 4,500% year to date. What started out as a joke has enabled some to laugh all the way to the bank.\nOn the other hand, skeptics about Dogecoin would be just as quick to note that it has given up more than 60% of its earlier gains. Anyone who jumped on the Dogecoin late is probably sitting on some hefty losses.\nRegardless of what your take is on Dogecoin, what really matters is where you should put your money now. One place to get some investment ideas is Robinhood's 100 most popular stocks list. Here are two popular Robinhood stocks that could crush Dogecoin going forward.\nImage source: Getty Images.\nNVIDIA\nWhile Dogecoin has nosedived in recent months, NVIDIA (NASDAQ:NVDA) stock has taken off. One reason why is NVIDIA's upcoming four-for-one stock split. While stock splits don't impact a company's valuation directly, they can attract greater numbers of small investors.\nHowever, there are plenty of even better reasons to like NVIDIA that have nothing to do with its stock split. The most obvious one is the company's gaming business.\nGaming remains NVIDIA's biggest moneymaker, generating $2.8 billion of the company's total revenue of nearly $5.7 billion in the first quarter of 2021. And business is booming. NVIDIA's gaming revenue more than doubled year over year.\nIt isn't just that gaming is increasing in popularity (although that is the case). NVIDIA benefits from regular hardware upgrade cycles. New games require even more processing power, which drives demand for the more powerful graphics processing units (GPUs).\nI especially like that NVIDIA is leveraging its gaming expertise to target new markets. For example, the company recently unveiled Omniverse Enterprise, a platform where design teams can build 3D virtual simulations and collaborate in real-time. In effect, NVIDIA is turning work into play (or vice versa, depending on how you look at it).\nNVIDIA CFO Colette Kress said in the company's Q1 conference call, \"As the world becomes more digital, virtual and collaborative, we see a significant revenue opportunity for Omniverse.\" I think that Kress's optimism is well-founded.\nDon't overlook NVIDIA's potential in the data center market, though. The company posted data center revenue of more than $2 billion in Q1, up 79% year over year. NVIDIA should enjoy sustained growth as more applications include artificial intelligence (AI).\nAssuming NVIDIA's pending acquisition of Arm passes regulatory hurdles, the company should further cement its leadership position in AI. In particular, the Arm deal would boost NVIDIA's presence in the fast-growing Internet of Things market with chips for mobile devices.\nSure, an overall cryptocurrency crash could cause NVIDIA's shares to fall due to the popularity of the company's GPUs with crypto miners. It's happened before. However, the company has taken steps to segment its gaming business from crypto. I think that any pullback would only be temporary. NVIDIA has too many other strong growth drivers.\nModerna\nMost companies can't honestly say that they've helped change the world. Moderna (NASDAQ:MRNA) can.\nThe biotech's COVID-19 vaccine was second only to the vaccine developed by Pfizer and BioNTech to win U.S. Emergency Use Authorization (EUA). Moderna reported $1.9 billion in sales for the vaccine in Q1, but that's just the tip of the iceberg.\nBased on supply agreements in place as of early May, Moderna projected that its COVID-19 vaccine would rake in sales this year of $19.2 billion. However, the company has secured additional deals since then.\nIn just the past two weeks, Moderna has landed two new huge supply agreements. The U.S. government is buying 200 million additional doses of Moderna's COVID19 vaccine. The European Commission agreed to purchase another 150 million doses.\nBut does Moderna's market cap of close to $90 billion already price all of this growth in? To some extent, yes. However, shares still are trading at only around 10.5 times expected earnings. That's an attractive valuation, especially for a biotech stock.\nThe big question for Moderna is how strong the recurring revenue from its COVID-19 vaccine will be. While the sales levels of 2021 and 2022 might not be sustainable over the long run, annual vaccinations could be likely (especially with emerging coronavirus variants). I expect Moderna will be able to count on significant COVID-19 vaccine sales for years to come.\nThen there's the pipeline. Moderna plans to advance its cytomegalovirus (CMV) vaccine into late-stage testing this year. It could easily be a megablockbuster if approved. The company has a dozen other programs in clinical testing.\nModerna hopes to use its newfound riches to dramatically boost its pipeline in the near future. CEO Stephane Bancel has stated that he'd like to have up to 50 clinical programs.\nAll of Moderna's current and planned pipeline programs are based on its messenger RNA (mRNA) technology. The company has maintained for a long time that if its mRNA approach worked for one disease, it would work for many diseases. If Moderna is right, the biotech stock should be a massive winner over the long run -- and could very well crush Dogecoin.","news_type":1},"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149876016,"gmtCreate":1625718310035,"gmtModify":1633938032523,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"The irony of how biotech should help better lives versus earning lots of profits is always a debatable question.&nbsp;","listText":"The irony of how biotech should help better lives versus earning lots of profits is always a debatable question.&nbsp;","text":"The irony of how biotech should help better lives versus earning lots of profits is always a debatable question.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/149876016","repostId":"2149365051","repostType":4,"repost":{"id":"2149365051","pubTimestamp":1625648700,"share":"https://www.laohu8.com/m/news/2149365051?lang=&edition=full","pubTime":"2021-07-07 17:05","market":"us","language":"en","title":"3 Biotechs to Avoid Like the Plague in July","url":"https://stock-news.laohu8.com/highlight/detail?id=2149365051","media":"Motley Fool","summary":"Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.","content":"<p>Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-lifetime pandemic. The sector is not without its risks, however. A few small-cap players using questionable science have sold investors on false dreams of miracle drugs that could become game-changers in their field, and in these cases, that couldn't be further from the truth.&nbsp;</p>\n<p>Avoiding bad investments is just as important as making good ones. So let's look at the dark side of investing in biotech and which companies to stay well away from.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6bccd5c36f3f76148be467937b9b6293\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>1. Cel-Sci</h2>\n<p>Sometimes, <a href=\"https://laohu8.com/S/AONE\">one</a> is dealt a bad hand in life and will need to bluff. However, it's a whole different story to double down on a bluff after <a href=\"https://laohu8.com/S/AONE.U\">one</a>'s cover is blown.&nbsp;</p>\n<p>Take the case of&nbsp;<b>Cel-Sci&nbsp;</b>(NYSEMKT:CVM), a small-cap biotech with a single late-stage immunotherapy candidate (Multikine) for treating head and neck cancer. On June 28, Cel-Sci announced that Multikine failed to achieve the primary endpoint of boosting patient survival by 10% compared to standard-of-care treatments in a decade-long phase 3 trial. As a result, the stock lost 66% of its value within four days, to $8.65.</p>\n<p>It's pretty hard to walk away from a giant bluff when there's just too much in the pot. In a conference call to investors on July 1, CEO Geert Kersten heralded the study as a \"success,\" saying that a cohort of patients who received Multikine plus surgery plus radiotherapy \"met the primary endpoint,\" and that Cel-Sci plans to file for regulatory approval. Later on in the call, chief scientific officer Taylor Eval denied all allegations the company was data-mining the study. On a side note, Kersten said he will \"not be releasing the [full] data to shareholders.\"</p>\n<p>The data that management is referring to is from a subgroup of patients in the Multikine cohort who did not receive chemotherapy in the study. This group of patients survived 14.3% longer after five years than the group who received no Multikine at all -- but that does not mean Multikine works on patients without chemotherapy. It has nothing to do with the study's primary endpoint (which includes both patients who did and did not receive chemotherapy). So the data-mining here is, in fact, pretty evident.</p>\n<p>It's also very easy to see how the drug could have a placebo effect. In clinical trials, Multikine was injected in or around the tumor. In case one was wondering, injecting just about anything into a tumor causes the cancer cells to die off -- partly due to needle damage. Moreover, patients in the 9.5-year study received Multikine for just three weeks and were not treated with the drug if their cancer relapsed. So anything (such as lifestyle choices, receiving other immunotherapies post-relapse, etc.) could have been behind the survival difference in the subgroups.</p>\n<p>Before the results came out (which took over a year), Cel-Sci bagged $31.7 million in cash by selling new stock to retail investors, resulting in heavy losses for shareholders less than three weeks after the deal closed. Overall, given the failure of its flagship candidate, the less than $50 million in assets on its books, and questionable conduct from management, this is definitely a biotech you don't want to be holding anytime soon (if not ever).&nbsp;</p>\n<h2>2. CytoDyn&nbsp;</h2>\n<p><b>CytoDyn</b> (OTC:CYDY) is a biotech known for developing leronlimab, an antibody that failed two phase 3 clinical studies for treating COVID-19. In May, the U.S. Food and Drug Administration (FDA) even released a rare statement saying that the drug did not meet the primary endpoints in these studies.&nbsp;</p>\n<p>In response, CEO Nader Pourhassan has adopted a \"catch me if you can\" type of strategy. In other words, CytoDyn simply moved outside of the FDA's jurisdiction and began commercializing the drug in countries like the Philippines.&nbsp;</p>\n<p>It's perplexing as to why the company would risk its relationship with the FDA like this. Aside from the COVID-19 indication, leronlimab is also under investigation for the treatment of HIV. In one study, leronlimab reduced viral load to negligible levels in 83% of patients with HIV.</p>\n<p>I wouldn't be surprised if the rivalry between Pourhassan and the FDA has gone down to the personal level. Last July, the FDA rejected CytoDyn's Biologic License Application (BLA) filing for leronlimab's approval for treating HIV. But the agency did not ask for another clinical trial; it just wanted additional information about the drug and a meeting with company management. CytoDyn has just begun the process to resubmit its BLA on July 1, almost a year later.</p>\n<p>At the end of the day, biotechs with sketchy science and management woes shouldn't be trading at a $1 billion market cap. Take note that CytoDyn has less than $150 million in total assets, leaving shareholders with little recourse in case of further blunders.&nbsp;</p>\n<h2>3. Northwest Biotherapeutics&nbsp;</h2>\n<p><b>Northwest Biotherapeutics</b>&nbsp;(OTC:NWBO) is a company that closely mirrors Cel-Sci in terms of both its science and stock price. Its management is also even more \"audacious\" than that of the previous companies.&nbsp;</p>\n<p>The company's flagship candidate is an immunotherapy known as DCVax-L, which is under investigation for the treatment of glioblastoma multiforme, the most deadly form of brain cancer. The phase 3 study has been going on since December 2006 (almost 15 years now). It was originally a phase 2 study, but the company \"phase-shifted\" it to 3, citing difficulty in finding patients who are comfortable taking a placebo for the deadly illness.</p>\n<p>The study had numerous red flags from the start. Northwest was supposed to conduct two interim analyses of the trial data starting in December 2013. Yes, you read that right, December of 2013. By August 2014, however, the company had released a statement claiming that \"no interim analysis of efficacy in the Phase III trial [had] been done.\" What's more, the FDA halted the DCVax-L clinical trial in August 2015 before lifting it two years later. To this day, Northwest's management has never explained the reasons behind the trial halt.</p>\n<p>The company did eventually perform the interim analyses in 2017 and 2018, but released the results unblinded. When it comes to deadly diseases with significant unmet needs, clinical trials can be stopped early if the experimental drug meets the primary endpoint for ethical reasons. That did not happen with DCVax-L on both occasions.</p>\n<p>Last October, Northwest finally announced that the trial was coming to its end and that data was to be sent for statistical analysis. It's been more than nine months since the announcement, and no news. But, again, from an ethical endpoint, if DCVax-L was working, it doesn't make sense that Northwest wouldn't release top-line data and rush the drug to approval to save lives.</p>\n<p>Shareholders should be expecting a lot of pain ahead, as the company inexplicably has a market cap of $1.27 billion -- with an unpromising candidate and less than $35 million in total assets. All of this makes Northwest's fate look eerily similar to that of Cel-Sci -- and a stock to stay away from for good.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotechs to Avoid Like the Plague in July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotechs to Avoid Like the Plague in July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 17:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CYDY":"CytoDyn Inc.","CVM":"CEL-SCI Corp","NWBO":"西北生物疗法"},"source_url":"https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2149365051","content_text":"Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-lifetime pandemic. The sector is not without its risks, however. A few small-cap players using questionable science have sold investors on false dreams of miracle drugs that could become game-changers in their field, and in these cases, that couldn't be further from the truth. \nAvoiding bad investments is just as important as making good ones. So let's look at the dark side of investing in biotech and which companies to stay well away from. \nImage source: Getty Images.\n1. Cel-Sci\nSometimes, one is dealt a bad hand in life and will need to bluff. However, it's a whole different story to double down on a bluff after one's cover is blown. \nTake the case of Cel-Sci (NYSEMKT:CVM), a small-cap biotech with a single late-stage immunotherapy candidate (Multikine) for treating head and neck cancer. On June 28, Cel-Sci announced that Multikine failed to achieve the primary endpoint of boosting patient survival by 10% compared to standard-of-care treatments in a decade-long phase 3 trial. As a result, the stock lost 66% of its value within four days, to $8.65.\nIt's pretty hard to walk away from a giant bluff when there's just too much in the pot. In a conference call to investors on July 1, CEO Geert Kersten heralded the study as a \"success,\" saying that a cohort of patients who received Multikine plus surgery plus radiotherapy \"met the primary endpoint,\" and that Cel-Sci plans to file for regulatory approval. Later on in the call, chief scientific officer Taylor Eval denied all allegations the company was data-mining the study. On a side note, Kersten said he will \"not be releasing the [full] data to shareholders.\"\nThe data that management is referring to is from a subgroup of patients in the Multikine cohort who did not receive chemotherapy in the study. This group of patients survived 14.3% longer after five years than the group who received no Multikine at all -- but that does not mean Multikine works on patients without chemotherapy. It has nothing to do with the study's primary endpoint (which includes both patients who did and did not receive chemotherapy). So the data-mining here is, in fact, pretty evident.\nIt's also very easy to see how the drug could have a placebo effect. In clinical trials, Multikine was injected in or around the tumor. In case one was wondering, injecting just about anything into a tumor causes the cancer cells to die off -- partly due to needle damage. Moreover, patients in the 9.5-year study received Multikine for just three weeks and were not treated with the drug if their cancer relapsed. So anything (such as lifestyle choices, receiving other immunotherapies post-relapse, etc.) could have been behind the survival difference in the subgroups.\nBefore the results came out (which took over a year), Cel-Sci bagged $31.7 million in cash by selling new stock to retail investors, resulting in heavy losses for shareholders less than three weeks after the deal closed. Overall, given the failure of its flagship candidate, the less than $50 million in assets on its books, and questionable conduct from management, this is definitely a biotech you don't want to be holding anytime soon (if not ever). \n2. CytoDyn \nCytoDyn (OTC:CYDY) is a biotech known for developing leronlimab, an antibody that failed two phase 3 clinical studies for treating COVID-19. In May, the U.S. Food and Drug Administration (FDA) even released a rare statement saying that the drug did not meet the primary endpoints in these studies. \nIn response, CEO Nader Pourhassan has adopted a \"catch me if you can\" type of strategy. In other words, CytoDyn simply moved outside of the FDA's jurisdiction and began commercializing the drug in countries like the Philippines. \nIt's perplexing as to why the company would risk its relationship with the FDA like this. Aside from the COVID-19 indication, leronlimab is also under investigation for the treatment of HIV. In one study, leronlimab reduced viral load to negligible levels in 83% of patients with HIV.\nI wouldn't be surprised if the rivalry between Pourhassan and the FDA has gone down to the personal level. Last July, the FDA rejected CytoDyn's Biologic License Application (BLA) filing for leronlimab's approval for treating HIV. But the agency did not ask for another clinical trial; it just wanted additional information about the drug and a meeting with company management. CytoDyn has just begun the process to resubmit its BLA on July 1, almost a year later.\nAt the end of the day, biotechs with sketchy science and management woes shouldn't be trading at a $1 billion market cap. Take note that CytoDyn has less than $150 million in total assets, leaving shareholders with little recourse in case of further blunders. \n3. Northwest Biotherapeutics \nNorthwest Biotherapeutics (OTC:NWBO) is a company that closely mirrors Cel-Sci in terms of both its science and stock price. Its management is also even more \"audacious\" than that of the previous companies. \nThe company's flagship candidate is an immunotherapy known as DCVax-L, which is under investigation for the treatment of glioblastoma multiforme, the most deadly form of brain cancer. The phase 3 study has been going on since December 2006 (almost 15 years now). It was originally a phase 2 study, but the company \"phase-shifted\" it to 3, citing difficulty in finding patients who are comfortable taking a placebo for the deadly illness.\nThe study had numerous red flags from the start. Northwest was supposed to conduct two interim analyses of the trial data starting in December 2013. Yes, you read that right, December of 2013. By August 2014, however, the company had released a statement claiming that \"no interim analysis of efficacy in the Phase III trial [had] been done.\" What's more, the FDA halted the DCVax-L clinical trial in August 2015 before lifting it two years later. To this day, Northwest's management has never explained the reasons behind the trial halt.\nThe company did eventually perform the interim analyses in 2017 and 2018, but released the results unblinded. When it comes to deadly diseases with significant unmet needs, clinical trials can be stopped early if the experimental drug meets the primary endpoint for ethical reasons. That did not happen with DCVax-L on both occasions.\nLast October, Northwest finally announced that the trial was coming to its end and that data was to be sent for statistical analysis. It's been more than nine months since the announcement, and no news. But, again, from an ethical endpoint, if DCVax-L was working, it doesn't make sense that Northwest wouldn't release top-line data and rush the drug to approval to save lives.\nShareholders should be expecting a lot of pain ahead, as the company inexplicably has a market cap of $1.27 billion -- with an unpromising candidate and less than $35 million in total assets. All of this makes Northwest's fate look eerily similar to that of Cel-Sci -- and a stock to stay away from for good.","news_type":1},"isVote":1,"tweetType":1,"viewCount":263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154877681,"gmtCreate":1625510334443,"gmtModify":1633940144150,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"The true strength&nbsp;of Amazon isn't solely focused on the leader alone, but the rest of the business. Hopefully it sustains and grows!&nbsp;","listText":"The true strength&nbsp;of Amazon isn't solely focused on the leader alone, but the rest of the business. Hopefully it sustains and grows!&nbsp;","text":"The true strength of Amazon isn't solely focused on the leader alone, but the rest of the business. Hopefully it sustains and grows!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154877681","repostId":"1157317474","repostType":4,"isVote":1,"tweetType":1,"viewCount":279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158539514,"gmtCreate":1625154535338,"gmtModify":1631888920994,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JLB.SI\">$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$</a>&nbsp;hopefully it keeps going up!&nbsp;","listText":"<a href=\"https://laohu8.com/S/JLB.SI\">$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$</a>&nbsp;hopefully it keeps going up!&nbsp;","text":"$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$ hopefully it keeps going up!","images":[{"img":"https://static.tigerbbs.com/6c1bd42cf964b85c81960a4e99156b8b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158539514","isVote":1,"tweetType":1,"viewCount":226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":128883710,"gmtCreate":1624510097330,"gmtModify":1631884323408,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Hope it continues to go up!&nbsp;","listText":"Hope it continues to go up!&nbsp;","text":"Hope it continues to go up!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128883710","repostId":"1176854050","repostType":4,"repost":{"id":"1176854050","pubTimestamp":1624506221,"share":"https://www.laohu8.com/m/news/1176854050?lang=&edition=full","pubTime":"2021-06-24 11:43","market":"us","language":"en","title":"Tesla: A Lesson In Humility","url":"https://stock-news.laohu8.com/highlight/detail?id=1176854050","media":"seekingalpha","summary":"Tesla shares have pulled well back in a months-long period of weakness.With earnings coming up, there looks to be a showdown of bulls and bears on the near-term horizon.I see Tesla's fundamentals - and valuation - as having improved massively in recent months, and I'm therefore still quite bullish.Finally, the elephant in the room is the descending triangle I noted above, and I’ve added some extra bars at the end of the chart to show what the resolution of the triangle might look like. We can se","content":"<p><b>Summary</b></p>\n<ul>\n <li>Tesla shares have pulled well back in a months-long period of weakness.</li>\n <li>With earnings coming up, there looks to be a showdown of bulls and bears on the near-term horizon.</li>\n <li>I see Tesla's fundamentals - and valuation - as having improved massively in recent months, and I'm therefore still quite bullish.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/16088600ba424779ab370711976bff68\" tg-width=\"768\" tg-height=\"397\" referrerpolicy=\"no-referrer\"><span>AdrianHancu/iStock Editorial via Getty Images</span></p>\n<p>Sometimes in investing, our thesis, no matter how much we believe in it, doesn’t work. I’ve experienced that countless times personally, and I think pretty much everyone who tries their hand at growing capital through the financial markets does as well. The important thing is not to fall in love with a stock and let it destroy your portfolio, and in the case of EV mothership<b>Tesla</b>(TSLA), I certainly had my fair share of practice at letting go of a failed thesis recently.</p>\n<p>Back inearly April, I said it was time to buy Tesla based upon its fairly reliable history of running higher into earnings announcements. The stock was at $691 at the time and did move higher in the next couple of weeks, but as we can see from the below, the move didn’t stick. That caused me to rethink my position in the short-term with Tesla, and now that we are four weeks out from the next earnings report, we have a different situation on our hands.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/54fd49361e0720105b3d38a4c4c88fa1\" tg-width=\"640\" tg-height=\"615\" referrerpolicy=\"no-referrer\"><span>Source: StockCharts</span></p>\n<p>I’ve annotated several things on the daily chart because the situation is quite interesting for Tesla during this critical period leading up to the next earnings release. The first thing I’ll note is that the accumulation/distribution line remains very strong, having never wavered from its prior levels achieved during the massive rally that took place mostly in 2020. That’s a good sign because the bulls and bears remain roughly equally matched despite a share price that has given the bulls every reason to move on.</p>\n<p>Momentum is more of a mixed picture because the PPO and 14-day RSI are both showing some signs of positive divergence, but also signs that bullish momentum is nowhere near high enough to push the stock into another rally phase. On the divergence side, momentum is gradually moving higher while the share price bounces around, indicating that the worst of the selling is likely done, but that we’re in a digestion period. The 14-day RSI hasn’t yet crested the centerline in earnest, which again means that bullish momentum is fairly weak.</p>\n<p>Overall, I’d say momentum is showing what you might expect at this stage, which is that the selling pressure has abated, but we’re not in rally mode. Yet.</p>\n<p>Finally, the elephant in the room is the descending triangle I noted above, and I’ve added some extra bars at the end of the chart to show what the resolution of the triangle might look like. We can see at the current slope of the line that the triangle will likely resolve near the end of July, which just so happens to coincide with the earnings release. This is a bearish pattern so I don’t want to make everything seem like sunshine and lollipops, but the rest of the chart is mixed, so we’ll have to wait and see.</p>\n<p>The earnings report, in my view, is going to be the catalyst one way or the other for the breakout from the triangle. Which direction it will go is anyone’s guess, but I’d be ready for a wild reaction to the earnings release in July.</p>\n<p>If we look at a weekly chart, I see a much rosier picture.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ef4525c330221c7768acc84c336cd8ef\" tg-width=\"640\" tg-height=\"615\" referrerpolicy=\"no-referrer\"><span>Source: StockCharts</span></p>\n<p>We can see that the stock ran up massively in 2020 and took with it the accumulation/distribution line, as well as the momentum indicators, as you’d expect. But since the selling began, we see signs that the stock has simply worked off its overbought conditions, which looks bullish to me.</p>\n<p>The 50-week moving average has served as support during this consolidation phase, and it currently stands at $575, so I’d watch that level if we see more selling. On the plus side, the accumulation/distribution line looks beautiful and again, is supportive of this selling being a digestion period rather than the end of the bull market for Tesla.</p>\n<p>Momentum would seem to support that as well, as the PPO and 14-week RSI are back at centerline support. What happens after this is critical, obviously, but the weekly chart doesn’t show Tesla as breaking down on a longer-term basis. The negative divergences we saw since 2020 began have given way to momentum resetting, which often happens before a new bull phase begins. With the earnings report looming in July, and the daily and weekly charts showing different pictures (at least to my eye), it’s going to be an interesting next four weeks for sure.</p>\n<p><b>Fundamentals still bullish</b></p>\n<p>I’d sum up the chart as having a short-term set of challenges for the bulls, but longer-term, I still see Tesla going higher. On a fundamental basis, I think the conclusion is decidedly more bullish. Let’s start with revenue revisions, which have been nothing short of terrific.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7297a6360a43284ab70d4caf12d206f3\" tg-width=\"640\" tg-height=\"282\" referrerpolicy=\"no-referrer\"><span>Source:Seeking Alpha</span></p>\n<p>All years are showing uptrends in revenue revisions, and in particular, the out years. Let us not forget that these positive revisions are occurring during a time when countless startups and internal combustion engine OGs like GM (GM), Ford (F) and Volkswagen (OTCPK:VWAGY) are investing tens of billions of dollars to take market share in EVs. None of this is new and it isn’t like the analyst community is surprised by these investments; Tesla is simply on a tremendous upward trajectory when it comes to growing revenue.</p>\n<p>Canaccordpointed out last week that the Model S Plaid Plus delay was likely due to the 4680 cell design not being ready for prime time. That very well could be the case, and it wouldn’t be the first time Tesla disappointed with a time frame it gave investors. Remember therobo-taxi claim?</p>\n<p>At any rate, the company’s lineup continues to resonate with customers and now that capacity constraints should lessen greatly over the coming years – new factories in a few parts of the world will help – the path of least resistance for Tesla is no doubt higher. This will only get better as Tesla can decrease the per-unit cost of things like the batteries so it can better compete with mainstream automakers on price, and become a mainstream automaker rather than a niche manufacturer for the well-heeled.</p>\n<p>Another thing scale is affording Tesla is monumental progress with profit margins. Below we have trailing-twelve-months gross margins, SG&amp;A costs, and EBIT margin as a percentage of revenue.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f9effb44d7bda8f3bdb535e80dd1ac0f\" tg-width=\"640\" tg-height=\"168\" referrerpolicy=\"no-referrer\"><span>Source: TIKR.com</span></p>\n<p>All three of these lines are moving in the right direction. Gross margins have been rising thanks to higher sales and production volumes, a trend that should continue so long as sales remain robust. In addition, Tesla is spending much less on an SG&amp;A basis than it used to, which again, is the product of higher sales volume. SG&amp;A used to be in the mid-20% range of revenue, which is unsustainable. Today, it’s only 10%, which means operating margins have gone quite positive, and with room to run in the future.</p>\n<p>Margins have always been an easy thing for the bears to point to, but that is simply no longer the case, and if you have a long holding period, the margin situation is going to work out in the bulls’ favor.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6401d5cd793a93d0ed6d36f911abdb15\" tg-width=\"640\" tg-height=\"283\" referrerpolicy=\"no-referrer\"><span>Source:Seeking Alpha</span></p>\n<p>This is all pointing to ever-higher EPS estimates, as we can see above. Analysts continue to try and keep up with Tesla’s upward trajectory, and so long as sales volumes and margins continue their march higher, so will these lines. Again, this is a feather in the cap of the bulls.</p>\n<p><b>Other considerations</b></p>\n<p>Tesla is not for the faint of heart, because it is volatile and we are at a point in the history of the automobile that an EV gold rush of sorts is occurring. Everyone is investing to win once the internal combustion engine is gone, but Tesla has a massive head start on the competition.</p>\n<p>Even so, there are risks to consider. First, Tesla could lose its technology lead over time as legacy manufacturers throw tens of billions of dollars at R&amp;D on battery technology. Tesla is far and away the superior battery maker today, but that does not guarantee it stays that way. To be clear, I don’t see that as a viable outcome in the near-term, but ten years from now? Twenty? It's a risk.</p>\n<p>Another risk is that Tesla uses its stock as a piggy bank, issuing shares to fund R&amp;D, factory construction, and the like.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b8f44f661051d87ad3f2906cabe5479d\" tg-width=\"640\" tg-height=\"165\" referrerpolicy=\"no-referrer\"><span>Source: TIKR.com</span></p>\n<p>The share count has nearly doubled in the past decade, which is pretty ugly from a shareholders’ perspective, as we usually only see this kind of dilution with REITs or BDCs that issue equity capital as a normal course of business. Manufacturing stocks don’t generally do anything like this, but Tesla has made it work. Still, you have to imagine it is possible that over a decade holding period, you’ll be diluted out of half of your ownership in the company. This also creates an uphill battle for EPS as earnings are spread over more and more shares, so I want to be clear this is an unequivocal negative for shareholders. However, let me now point you to what could possibly be the saving grace for this perma-dilution; free cash flow.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0569f35589cc0f82bb006148271df19b\" tg-width=\"640\" tg-height=\"170\" referrerpolicy=\"no-referrer\"><span>Source: TIKR.com</span></p>\n<p>Tesla’s trailing-twelve-months FCF has improved immensely in recent years, as the company is producing massive amounts of operating cash flow that it never did before, which is owed once again to sales volume and margin growth. Tesla has surpassed the point where it needs to constantly issue capital just to survive because it is creating its own through its operations. This is massively important for the bull case because it means the dilution we’ve seen in recent years<i>shouldn’t</i>be necessary any longer.</p>\n<p>Indeed, if we look at net debt, we can see just how much Tesla’s balance sheet has improved, which again supports not having to dilute shareholders to stay afloat.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/49fa413fc33c85d7269e987b2c11c888\" tg-width=\"640\" tg-height=\"169\" referrerpolicy=\"no-referrer\"><span>Source: TIKR.com</span></p>\n<p>Net debt has turned into a net cash position of late, with Tesla having nearly $5 billion in cash and equivalents more than debt. Tesla’s financing situation has improved enormously, and that’s good for those of us that are bullish.</p>\n<p><b>Is it cheap?</b></p>\n<p>Not really. But then again revolutionary companies rarely are. The good news is that the price-to-sales ratio has halved since the peak earlier this year, but at 11x forward revenue, I cannot in good conscience call it cheap.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ca2d9f38636872d9d508e096e9ac8af8\" tg-width=\"640\" tg-height=\"189\" referrerpolicy=\"no-referrer\"><span>Source: TIKR.com</span></p>\n<p>However, it is a lot cheaper than it was, and withrevenueslated to rise by more than half this year, and then<i>double</i>again by 2024, you don’t need the multiple to rise for a bullish outlook.</p>\n<p>I’ll reiterate that there are risks to Tesla. The daily chart is leaning slightly bearish with that descending triangle, but we’re heading into the pre-earnings run-up that Tesla<i>usually</i>shines during. The weekly chart is showing signs of digestion rather than rolling over. There are competitive risks that aren’t new and will never go way, but the company is still building great EVs that are resonating with customers. Margins and FCF are booming comparatively speaking, and the stock is at roughly half the valuation it was a few months ago.</p>\n<p>All in all, Tesla almost certainly has a rocky road in front of it, but I’m still bullish given the weight of the evidence.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla: A Lesson In Humility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla: A Lesson In Humility\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 11:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4436295-tesla-a-lesson-in-humility><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nTesla shares have pulled well back in a months-long period of weakness.\nWith earnings coming up, there looks to be a showdown of bulls and bears on the near-term horizon.\nI see Tesla's ...</p>\n\n<a href=\"https://seekingalpha.com/article/4436295-tesla-a-lesson-in-humility\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://seekingalpha.com/article/4436295-tesla-a-lesson-in-humility","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1176854050","content_text":"Summary\n\nTesla shares have pulled well back in a months-long period of weakness.\nWith earnings coming up, there looks to be a showdown of bulls and bears on the near-term horizon.\nI see Tesla's fundamentals - and valuation - as having improved massively in recent months, and I'm therefore still quite bullish.\n\nAdrianHancu/iStock Editorial via Getty Images\nSometimes in investing, our thesis, no matter how much we believe in it, doesn’t work. I’ve experienced that countless times personally, and I think pretty much everyone who tries their hand at growing capital through the financial markets does as well. The important thing is not to fall in love with a stock and let it destroy your portfolio, and in the case of EV mothershipTesla(TSLA), I certainly had my fair share of practice at letting go of a failed thesis recently.\nBack inearly April, I said it was time to buy Tesla based upon its fairly reliable history of running higher into earnings announcements. The stock was at $691 at the time and did move higher in the next couple of weeks, but as we can see from the below, the move didn’t stick. That caused me to rethink my position in the short-term with Tesla, and now that we are four weeks out from the next earnings report, we have a different situation on our hands.\nSource: StockCharts\nI’ve annotated several things on the daily chart because the situation is quite interesting for Tesla during this critical period leading up to the next earnings release. The first thing I’ll note is that the accumulation/distribution line remains very strong, having never wavered from its prior levels achieved during the massive rally that took place mostly in 2020. That’s a good sign because the bulls and bears remain roughly equally matched despite a share price that has given the bulls every reason to move on.\nMomentum is more of a mixed picture because the PPO and 14-day RSI are both showing some signs of positive divergence, but also signs that bullish momentum is nowhere near high enough to push the stock into another rally phase. On the divergence side, momentum is gradually moving higher while the share price bounces around, indicating that the worst of the selling is likely done, but that we’re in a digestion period. The 14-day RSI hasn’t yet crested the centerline in earnest, which again means that bullish momentum is fairly weak.\nOverall, I’d say momentum is showing what you might expect at this stage, which is that the selling pressure has abated, but we’re not in rally mode. Yet.\nFinally, the elephant in the room is the descending triangle I noted above, and I’ve added some extra bars at the end of the chart to show what the resolution of the triangle might look like. We can see at the current slope of the line that the triangle will likely resolve near the end of July, which just so happens to coincide with the earnings release. This is a bearish pattern so I don’t want to make everything seem like sunshine and lollipops, but the rest of the chart is mixed, so we’ll have to wait and see.\nThe earnings report, in my view, is going to be the catalyst one way or the other for the breakout from the triangle. Which direction it will go is anyone’s guess, but I’d be ready for a wild reaction to the earnings release in July.\nIf we look at a weekly chart, I see a much rosier picture.\nSource: StockCharts\nWe can see that the stock ran up massively in 2020 and took with it the accumulation/distribution line, as well as the momentum indicators, as you’d expect. But since the selling began, we see signs that the stock has simply worked off its overbought conditions, which looks bullish to me.\nThe 50-week moving average has served as support during this consolidation phase, and it currently stands at $575, so I’d watch that level if we see more selling. On the plus side, the accumulation/distribution line looks beautiful and again, is supportive of this selling being a digestion period rather than the end of the bull market for Tesla.\nMomentum would seem to support that as well, as the PPO and 14-week RSI are back at centerline support. What happens after this is critical, obviously, but the weekly chart doesn’t show Tesla as breaking down on a longer-term basis. The negative divergences we saw since 2020 began have given way to momentum resetting, which often happens before a new bull phase begins. With the earnings report looming in July, and the daily and weekly charts showing different pictures (at least to my eye), it’s going to be an interesting next four weeks for sure.\nFundamentals still bullish\nI’d sum up the chart as having a short-term set of challenges for the bulls, but longer-term, I still see Tesla going higher. On a fundamental basis, I think the conclusion is decidedly more bullish. Let’s start with revenue revisions, which have been nothing short of terrific.\nSource:Seeking Alpha\nAll years are showing uptrends in revenue revisions, and in particular, the out years. Let us not forget that these positive revisions are occurring during a time when countless startups and internal combustion engine OGs like GM (GM), Ford (F) and Volkswagen (OTCPK:VWAGY) are investing tens of billions of dollars to take market share in EVs. None of this is new and it isn’t like the analyst community is surprised by these investments; Tesla is simply on a tremendous upward trajectory when it comes to growing revenue.\nCanaccordpointed out last week that the Model S Plaid Plus delay was likely due to the 4680 cell design not being ready for prime time. That very well could be the case, and it wouldn’t be the first time Tesla disappointed with a time frame it gave investors. Remember therobo-taxi claim?\nAt any rate, the company’s lineup continues to resonate with customers and now that capacity constraints should lessen greatly over the coming years – new factories in a few parts of the world will help – the path of least resistance for Tesla is no doubt higher. This will only get better as Tesla can decrease the per-unit cost of things like the batteries so it can better compete with mainstream automakers on price, and become a mainstream automaker rather than a niche manufacturer for the well-heeled.\nAnother thing scale is affording Tesla is monumental progress with profit margins. Below we have trailing-twelve-months gross margins, SG&A costs, and EBIT margin as a percentage of revenue.\nSource: TIKR.com\nAll three of these lines are moving in the right direction. Gross margins have been rising thanks to higher sales and production volumes, a trend that should continue so long as sales remain robust. In addition, Tesla is spending much less on an SG&A basis than it used to, which again, is the product of higher sales volume. SG&A used to be in the mid-20% range of revenue, which is unsustainable. Today, it’s only 10%, which means operating margins have gone quite positive, and with room to run in the future.\nMargins have always been an easy thing for the bears to point to, but that is simply no longer the case, and if you have a long holding period, the margin situation is going to work out in the bulls’ favor.\nSource:Seeking Alpha\nThis is all pointing to ever-higher EPS estimates, as we can see above. Analysts continue to try and keep up with Tesla’s upward trajectory, and so long as sales volumes and margins continue their march higher, so will these lines. Again, this is a feather in the cap of the bulls.\nOther considerations\nTesla is not for the faint of heart, because it is volatile and we are at a point in the history of the automobile that an EV gold rush of sorts is occurring. Everyone is investing to win once the internal combustion engine is gone, but Tesla has a massive head start on the competition.\nEven so, there are risks to consider. First, Tesla could lose its technology lead over time as legacy manufacturers throw tens of billions of dollars at R&D on battery technology. Tesla is far and away the superior battery maker today, but that does not guarantee it stays that way. To be clear, I don’t see that as a viable outcome in the near-term, but ten years from now? Twenty? It's a risk.\nAnother risk is that Tesla uses its stock as a piggy bank, issuing shares to fund R&D, factory construction, and the like.\nSource: TIKR.com\nThe share count has nearly doubled in the past decade, which is pretty ugly from a shareholders’ perspective, as we usually only see this kind of dilution with REITs or BDCs that issue equity capital as a normal course of business. Manufacturing stocks don’t generally do anything like this, but Tesla has made it work. Still, you have to imagine it is possible that over a decade holding period, you’ll be diluted out of half of your ownership in the company. This also creates an uphill battle for EPS as earnings are spread over more and more shares, so I want to be clear this is an unequivocal negative for shareholders. However, let me now point you to what could possibly be the saving grace for this perma-dilution; free cash flow.\nSource: TIKR.com\nTesla’s trailing-twelve-months FCF has improved immensely in recent years, as the company is producing massive amounts of operating cash flow that it never did before, which is owed once again to sales volume and margin growth. Tesla has surpassed the point where it needs to constantly issue capital just to survive because it is creating its own through its operations. This is massively important for the bull case because it means the dilution we’ve seen in recent yearsshouldn’tbe necessary any longer.\nIndeed, if we look at net debt, we can see just how much Tesla’s balance sheet has improved, which again supports not having to dilute shareholders to stay afloat.\nSource: TIKR.com\nNet debt has turned into a net cash position of late, with Tesla having nearly $5 billion in cash and equivalents more than debt. Tesla’s financing situation has improved enormously, and that’s good for those of us that are bullish.\nIs it cheap?\nNot really. But then again revolutionary companies rarely are. The good news is that the price-to-sales ratio has halved since the peak earlier this year, but at 11x forward revenue, I cannot in good conscience call it cheap.\nSource: TIKR.com\nHowever, it is a lot cheaper than it was, and withrevenueslated to rise by more than half this year, and thendoubleagain by 2024, you don’t need the multiple to rise for a bullish outlook.\nI’ll reiterate that there are risks to Tesla. The daily chart is leaning slightly bearish with that descending triangle, but we’re heading into the pre-earnings run-up that Teslausuallyshines during. The weekly chart is showing signs of digestion rather than rolling over. There are competitive risks that aren’t new and will never go way, but the company is still building great EVs that are resonating with customers. Margins and FCF are booming comparatively speaking, and the stock is at roughly half the valuation it was a few months ago.\nAll in all, Tesla almost certainly has a rocky road in front of it, but I’m still bullish given the weight of the evidence.","news_type":1},"isVote":1,"tweetType":1,"viewCount":88,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":110486826,"gmtCreate":1622488094065,"gmtModify":1634101180963,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Hmmm.&nbsp;","listText":"Hmmm.&nbsp;","text":"Hmmm.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/110486826","repostId":"1133890180","repostType":4,"repost":{"id":"1133890180","pubTimestamp":1622468284,"share":"https://www.laohu8.com/m/news/1133890180?lang=&edition=full","pubTime":"2021-05-31 21:38","market":"us","language":"en","title":"How Much Is Coinbase Worth?","url":"https://stock-news.laohu8.com/highlight/detail?id=1133890180","media":"seekingalpha","summary":"Summary\n\nCOIN is a leading cryptocurrency infrastructure company.\nCOIN is investing aggressively in ","content":"<p><b>Summary</b></p>\n<ul>\n <li>COIN is a leading cryptocurrency infrastructure company.</li>\n <li>COIN is investing aggressively in cryptocurrency innovation in order to reduce dependency on its no-moat crypto trading fee business.</li>\n <li>What are COIN shares worth today? We detail our full valuation model.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e9c9e391ae4abc39a8e464c026fc0b0d\" tg-width=\"1536\" tg-height=\"1024\"><span>Photo by Movus/iStock Editorial via Getty Images</span></p>\n<p>As we detailed in our full investment thesis&nbsp;<i>Forget Bitcoin - 5 Reasons To Buy Coinbase Instead</i>, Coinbase(NASDAQ:COIN)&nbsp;is a leading cryptocurrency infrastructure company that is investing aggressively in cryptocurrency innovation in order to reduce dependency on its no-moat crypto trading fee business.</p>\n<p>What are COIN shares worth today? In the following sections, we will attempt to give an estimate.</p>\n<p><b>#1. Qualitative Analysis</b></p>\n<p>In order to provide the proper context for our quantitative assumptions and analysis we will briefly outline our qualitative appraisal of the company here.</p>\n<p><b>Diversified</b></p>\n<p>COIN is not solely dependent on the fate of any single cryptocurrency as it deals in over 100 cryptocurrencies on its platform. Furthermore, it is not confined to simply profiting off of cryptocurrency trading fees.</p>\n<p>While it is true that its cryptocurrency trading platform benefits from a large network effect and early-mover status, there is no lasting moat here given that competition is plentiful and growing and the retail investing crowd typically cares more about fees than anything else, making it a highly commoditized service.</p>\n<p>COIN's management sees this trend forming and realizes that it cannot maintain its fat 60.2% EBITDA margins forever by simply relying on transaction fees. Therefore it is investing aggressively to&nbsp;diversify into ancillary businesses&nbsp;like cryptocurrency rewards credit card through a partnership with Visa (V),Coinbase Prime&nbsp;(a prime brokerage product for custody, advanced trading, data analytics, and prime services targeting institutional and corporate investors), cybersecurity services tailored to blockchain and cryptocurrency, and loans and deposit accounts. In fact, within 5 years they expect to derive&nbsp;the majority of their revenue&nbsp;from outside of transaction fees.</p>\n<p><b>Profitable</b></p>\n<p>Even though its cryptocurrency transaction business may not have much of a moat and we do not expect its fat margins to be sustainable, it is current wildly profitable as returns on invested capital were a whopping 48.4% over the past twelve months and the company is expected to generate $8.41 in normalized earnings per share this year.</p>\n<p>As a result of their profitable business, they have a net cash position and nearly $2 billion in cash on their balance sheet, giving them plenty of dry powder to not only avoid financial distress but also continue to invest opportunistically in growing into ancillary businesses.</p>\n<p><b>Not Directly Correlated to the Bitcoin (BTC-USD) Price</b></p>\n<p>Given that COIN profits from transaction fees and ancillary services, its revenues are not directly tied to the price of Bitcoin or other cryptocurrencies. Instead, they are more closely tied to the volume of transactions and other uses of cryptocurrencies. As a result, they tend to rack up large profits when cryptocurrencies are either on a strong bull run or in a fierce downturn.</p>\n<p><b>Massive Growth Potential</b></p>\n<p>Last, but not least, we expect COIN to grow significantly in the years to come, provided that cryptocurrencies and blockchain technology continue their strong growth trajectory.</p>\n<p>Between their strong crypto and software brain trust, their stakes in numerous cryptocurrency and blockchain startups which are developing innovative products and services using the technology, and their massive growth runway from their current 50 million users to an estimated 1 billion potential customers, they could very well enjoy an exponential growth trajectory.</p>\n<p>We are particularly bullish on their institutional investor services business potential, which should help them more than offset expected tightening margins in their retail exchange business.</p>\n<p><b>#2. Quantitative Analysis</b></p>\n<p>While all this sounds great, the main question remains: what is COIN worth?</p>\n<p>The company is currently appraised by Mr. Market to be worth an Enterprise Value of $50.8 billion and is expected to generate ~$6.3 billion in revenue in 2021 followed by $5.9 billion in 2022. The EBITDA margin is expected to be 47.7% in 2021 and then decline to 39.2% in 2022 on declining revenue and increased competition in the exchange business.</p>\n<p>While these estimates are nice, if not useful to some extent, COIN's revenue and profitability are extremely hard to predict in any given year due to the asset-light nature of the business and its heavy dependence on exchange volume in an immature and rapidly evolving asset class.</p>\n<p>That said, a few things we are quite confident in are that:</p>\n<ol>\n <li>Exchange business margins will compress meaningfully in the years to come.</li>\n <li>COIN will continue to diversify rapidly away from its exchange business into ancillary businesses and within the next half decade these alternative sources of revenue should combine to exceed its exchange business revenue.</li>\n <li>COIN will remain profitable and a leader in the cryptocurrency/blockchain tech and services space given its financial and personnel resources and sector-leading scale and early-mover advantage.</li>\n <li>Blockchain technology is here to stay with many valuable applications and cryptocurrencies of some sort will likely also continue to grow in popularity and acceptance.</li>\n</ol>\n<p>Given these assumptions, here are a few possible scenarios and potential corresponding valuations for COIN:</p>\n<p><b>Model #1: \"Bear\" Case</b></p>\n<p>COIN struggles to deliver on its innovations and misses its target of generating the majority of its revenue outside of its exchange business within 5 years and/or cryptocurrencies run into major regulatory headwinds that lead to weak institutional adoption. As a result, retail investor demand also fizzles out and their exchange business also weakens considerably. In such a combination of scenarios, COIN is clearly dramatically overvalued at present and - while it likely will not go bankrupt given the utility of blockchain technology, their strong balance sheet, and the likelihood that some lingering demand will always exist for cryptocurrencies - investors at today's prices will be set up for dramatic losses.</p>\n<p><b>Model #2: \"Bull\" Case</b></p>\n<p>COIN's innovations take off as their startup investments reap significant rewards and their institutional business grows exponentially as broad institutional adoption of cryptocurrencies results in strong demand for secure storage and other services and products that COIN is in a highly competitive position to offer.</p>\n<p>Furthermore, this strong institutional demand provides rocket fuel to cryptocurrency prices, driving Bitcoin pricing into the hundreds of thousands of dollars and Ethereum (ETH-USD) pricing into the tends of thousands of dollars. Retail demand also then becomes even stronger as more and more participants enter the market and the fear of missing out drives people to put more and more of their wealth into crypto assets. This surge in demand will offset the heavy competition and COIN - as a major player in the exchange business - will see such strong demand that its margins will not compress as much as originally thought and revenue growth will lead to strong profit growth.</p>\n<p>In such a scenario, we expect annual exchange revenue to more than triple from 2021 levels by 2026 to hit $18 billion and net profit margins will only decline to ~25% ($4.5 billion in net profit from the exchange business).</p>\n<p>Meanwhile, their ancillary businesses will explode to consume 60% of their total revenue by 2026 at $27 billion and profit margins in these lucrative businesses will be ~45% ($12.2 billion in net profit from ancillary businesses). As a result, their total net income in 2026 will be ~$16.7 billion. Given their strength and growth, we assume a 20x multiple for the exchange business and a 35x multiple for the ancillary businesses, giving us a bull case valuation of $517 billion. That would represent a whopping 10x from current levels or a ~160% CAGR over the next half decade from current share prices.</p>\n<p><b>Model #3: \"Base\" Case</b></p>\n<p>COIN hits its target of generating the majority of its revenue outside of its exchange business within 5 years. We assume that exchange net income margins will decline significantly from their current levels to ~19% and revenue remains flat in that business as growth roughly offsets reduced fees. Meanwhile, however, ancillary businesses enjoy fat 40% net income margins due to COIN's technological advantages, asset-light business models, and economies of scale and revenues from these businesses are roughly 55% of their total revenue. As a result, we estimate 2026 revenue coming in at ~$14 billion and exchange net income at $1.2 billion and ancillary business net income coming in at $3.1 billion.</p>\n<p>We would conservatively value the exchange business at 15x net income and the ancillary business at 25x net income, resulting in an estimated value of $95.5 billion, or an 88% increase in valuation over 5 years. This would lead to a CAGR of 13.5% from current share price and make the stock an attractive buy here.</p>\n<p><b>Investor Takeaway</b></p>\n<p>As you can see from our models, valuing COIN is very challenging right now and the potential outcomes range from massive losses in a bear case scenario to enormous gains in a bull scenario. Our base case - based on a mildly bullish outlook for cryptocurrencies and their ancillary business investments, a realistically slightly bearish outlook for their exchange business, and conservative valuation multiple assumptions - indicates that COIN could be an attractive buy at present.</p>\n<p>While our current fair value estimate is ~$300 a share and implies meaningful upside from the current share price of ~$240, investors need to acknowledge that this is a highly speculative estimate at this point and that the thesis hinges primarily on their outlook for the growth of institutional cryptocurrency adoption rather than on internal factors at COIN. As a result, we rate COIN a speculative buy.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Much Is Coinbase Worth?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Much Is Coinbase Worth?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4432066-how-much-is-coinbase-worth><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nCOIN is a leading cryptocurrency infrastructure company.\nCOIN is investing aggressively in cryptocurrency innovation in order to reduce dependency on its no-moat crypto trading fee business.\n...</p>\n\n<a href=\"https://seekingalpha.com/article/4432066-how-much-is-coinbase-worth\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"source_url":"https://seekingalpha.com/article/4432066-how-much-is-coinbase-worth","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1133890180","content_text":"Summary\n\nCOIN is a leading cryptocurrency infrastructure company.\nCOIN is investing aggressively in cryptocurrency innovation in order to reduce dependency on its no-moat crypto trading fee business.\nWhat are COIN shares worth today? We detail our full valuation model.\n\nPhoto by Movus/iStock Editorial via Getty Images\nAs we detailed in our full investment thesis Forget Bitcoin - 5 Reasons To Buy Coinbase Instead, Coinbase(NASDAQ:COIN) is a leading cryptocurrency infrastructure company that is investing aggressively in cryptocurrency innovation in order to reduce dependency on its no-moat crypto trading fee business.\nWhat are COIN shares worth today? In the following sections, we will attempt to give an estimate.\n#1. Qualitative Analysis\nIn order to provide the proper context for our quantitative assumptions and analysis we will briefly outline our qualitative appraisal of the company here.\nDiversified\nCOIN is not solely dependent on the fate of any single cryptocurrency as it deals in over 100 cryptocurrencies on its platform. Furthermore, it is not confined to simply profiting off of cryptocurrency trading fees.\nWhile it is true that its cryptocurrency trading platform benefits from a large network effect and early-mover status, there is no lasting moat here given that competition is plentiful and growing and the retail investing crowd typically cares more about fees than anything else, making it a highly commoditized service.\nCOIN's management sees this trend forming and realizes that it cannot maintain its fat 60.2% EBITDA margins forever by simply relying on transaction fees. Therefore it is investing aggressively to diversify into ancillary businesses like cryptocurrency rewards credit card through a partnership with Visa (V),Coinbase Prime (a prime brokerage product for custody, advanced trading, data analytics, and prime services targeting institutional and corporate investors), cybersecurity services tailored to blockchain and cryptocurrency, and loans and deposit accounts. In fact, within 5 years they expect to derive the majority of their revenue from outside of transaction fees.\nProfitable\nEven though its cryptocurrency transaction business may not have much of a moat and we do not expect its fat margins to be sustainable, it is current wildly profitable as returns on invested capital were a whopping 48.4% over the past twelve months and the company is expected to generate $8.41 in normalized earnings per share this year.\nAs a result of their profitable business, they have a net cash position and nearly $2 billion in cash on their balance sheet, giving them plenty of dry powder to not only avoid financial distress but also continue to invest opportunistically in growing into ancillary businesses.\nNot Directly Correlated to the Bitcoin (BTC-USD) Price\nGiven that COIN profits from transaction fees and ancillary services, its revenues are not directly tied to the price of Bitcoin or other cryptocurrencies. Instead, they are more closely tied to the volume of transactions and other uses of cryptocurrencies. As a result, they tend to rack up large profits when cryptocurrencies are either on a strong bull run or in a fierce downturn.\nMassive Growth Potential\nLast, but not least, we expect COIN to grow significantly in the years to come, provided that cryptocurrencies and blockchain technology continue their strong growth trajectory.\nBetween their strong crypto and software brain trust, their stakes in numerous cryptocurrency and blockchain startups which are developing innovative products and services using the technology, and their massive growth runway from their current 50 million users to an estimated 1 billion potential customers, they could very well enjoy an exponential growth trajectory.\nWe are particularly bullish on their institutional investor services business potential, which should help them more than offset expected tightening margins in their retail exchange business.\n#2. Quantitative Analysis\nWhile all this sounds great, the main question remains: what is COIN worth?\nThe company is currently appraised by Mr. Market to be worth an Enterprise Value of $50.8 billion and is expected to generate ~$6.3 billion in revenue in 2021 followed by $5.9 billion in 2022. The EBITDA margin is expected to be 47.7% in 2021 and then decline to 39.2% in 2022 on declining revenue and increased competition in the exchange business.\nWhile these estimates are nice, if not useful to some extent, COIN's revenue and profitability are extremely hard to predict in any given year due to the asset-light nature of the business and its heavy dependence on exchange volume in an immature and rapidly evolving asset class.\nThat said, a few things we are quite confident in are that:\n\nExchange business margins will compress meaningfully in the years to come.\nCOIN will continue to diversify rapidly away from its exchange business into ancillary businesses and within the next half decade these alternative sources of revenue should combine to exceed its exchange business revenue.\nCOIN will remain profitable and a leader in the cryptocurrency/blockchain tech and services space given its financial and personnel resources and sector-leading scale and early-mover advantage.\nBlockchain technology is here to stay with many valuable applications and cryptocurrencies of some sort will likely also continue to grow in popularity and acceptance.\n\nGiven these assumptions, here are a few possible scenarios and potential corresponding valuations for COIN:\nModel #1: \"Bear\" Case\nCOIN struggles to deliver on its innovations and misses its target of generating the majority of its revenue outside of its exchange business within 5 years and/or cryptocurrencies run into major regulatory headwinds that lead to weak institutional adoption. As a result, retail investor demand also fizzles out and their exchange business also weakens considerably. In such a combination of scenarios, COIN is clearly dramatically overvalued at present and - while it likely will not go bankrupt given the utility of blockchain technology, their strong balance sheet, and the likelihood that some lingering demand will always exist for cryptocurrencies - investors at today's prices will be set up for dramatic losses.\nModel #2: \"Bull\" Case\nCOIN's innovations take off as their startup investments reap significant rewards and their institutional business grows exponentially as broad institutional adoption of cryptocurrencies results in strong demand for secure storage and other services and products that COIN is in a highly competitive position to offer.\nFurthermore, this strong institutional demand provides rocket fuel to cryptocurrency prices, driving Bitcoin pricing into the hundreds of thousands of dollars and Ethereum (ETH-USD) pricing into the tends of thousands of dollars. Retail demand also then becomes even stronger as more and more participants enter the market and the fear of missing out drives people to put more and more of their wealth into crypto assets. This surge in demand will offset the heavy competition and COIN - as a major player in the exchange business - will see such strong demand that its margins will not compress as much as originally thought and revenue growth will lead to strong profit growth.\nIn such a scenario, we expect annual exchange revenue to more than triple from 2021 levels by 2026 to hit $18 billion and net profit margins will only decline to ~25% ($4.5 billion in net profit from the exchange business).\nMeanwhile, their ancillary businesses will explode to consume 60% of their total revenue by 2026 at $27 billion and profit margins in these lucrative businesses will be ~45% ($12.2 billion in net profit from ancillary businesses). As a result, their total net income in 2026 will be ~$16.7 billion. Given their strength and growth, we assume a 20x multiple for the exchange business and a 35x multiple for the ancillary businesses, giving us a bull case valuation of $517 billion. That would represent a whopping 10x from current levels or a ~160% CAGR over the next half decade from current share prices.\nModel #3: \"Base\" Case\nCOIN hits its target of generating the majority of its revenue outside of its exchange business within 5 years. We assume that exchange net income margins will decline significantly from their current levels to ~19% and revenue remains flat in that business as growth roughly offsets reduced fees. Meanwhile, however, ancillary businesses enjoy fat 40% net income margins due to COIN's technological advantages, asset-light business models, and economies of scale and revenues from these businesses are roughly 55% of their total revenue. As a result, we estimate 2026 revenue coming in at ~$14 billion and exchange net income at $1.2 billion and ancillary business net income coming in at $3.1 billion.\nWe would conservatively value the exchange business at 15x net income and the ancillary business at 25x net income, resulting in an estimated value of $95.5 billion, or an 88% increase in valuation over 5 years. This would lead to a CAGR of 13.5% from current share price and make the stock an attractive buy here.\nInvestor Takeaway\nAs you can see from our models, valuing COIN is very challenging right now and the potential outcomes range from massive losses in a bear case scenario to enormous gains in a bull scenario. Our base case - based on a mildly bullish outlook for cryptocurrencies and their ancillary business investments, a realistically slightly bearish outlook for their exchange business, and conservative valuation multiple assumptions - indicates that COIN could be an attractive buy at present.\nWhile our current fair value estimate is ~$300 a share and implies meaningful upside from the current share price of ~$240, investors need to acknowledge that this is a highly speculative estimate at this point and that the thesis hinges primarily on their outlook for the growth of institutional cryptocurrency adoption rather than on internal factors at COIN. As a result, we rate COIN a speculative buy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":428,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802868778,"gmtCreate":1627755422494,"gmtModify":1631884081594,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"New leadership means it's either a change to bring the company forward, or vice versa. Hope it's&nbsp;the former!&nbsp;","listText":"New leadership means it's either a change to bring the company forward, or vice versa. Hope it's&nbsp;the former!&nbsp;","text":"New leadership means it's either a change to bring the company forward, or vice versa. Hope it's the former!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/802868778","repostId":"2155013045","repostType":4,"isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171151724,"gmtCreate":1626723016068,"gmtModify":1631889147616,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Too late to enter?&nbsp;","listText":"Too late to enter?&nbsp;","text":"Too late to enter?","images":[{"img":"https://static.tigerbbs.com/42219fdf52209378b59da8da9140fbdb","width":"1080","height":"3489"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/171151724","isVote":1,"tweetType":1,"viewCount":260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":179274848,"gmtCreate":1626544274584,"gmtModify":1631889147627,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Recent sharp increase. Will it keep going up?&nbsp;","listText":"Recent sharp increase. Will it keep going up?&nbsp;","text":"Recent sharp increase. Will it keep going up?","images":[{"img":"https://static.tigerbbs.com/994ed0ff59981c6ffb17b3bbe1d409b6","width":"1080","height":"3489"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179274848","isVote":1,"tweetType":1,"viewCount":359,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148770097,"gmtCreate":1626032993819,"gmtModify":1631889147676,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;still not going up as much as I hope. Keep rising, tesla!&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>&nbsp;still not going up as much as I hope. Keep rising, tesla!&nbsp;","text":"$Tesla Motors(TSLA)$ still not going up as much as I hope. Keep rising, tesla!","images":[{"img":"https://static.tigerbbs.com/da298c293b298102ce18978879e354d0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148770097","isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":143417632,"gmtCreate":1625808852926,"gmtModify":1631888361155,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Agree on the well explained part.&nbsp;//<a href=\"https://laohu8.com/U/3575196385895354\">@Cedric77</a>: Great article! Well explained on current down turn.&nbsp;","listText":"Agree on the well explained part.&nbsp;//<a href=\"https://laohu8.com/U/3575196385895354\">@Cedric77</a>: Great article! Well explained on current down turn.&nbsp;","text":"Agree on the well explained part. //@Cedric77: Great article! Well explained on current down turn.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143417632","repostId":"1162204971","repostType":4,"isVote":1,"tweetType":1,"viewCount":122,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123654712,"gmtCreate":1624422278736,"gmtModify":1634006331541,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Will be good if it does, won't it?&nbsp;","listText":"Will be good if it does, won't it?&nbsp;","text":"Will be good if it does, won't it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123654712","repostId":"1186919064","repostType":2,"isVote":1,"tweetType":1,"viewCount":126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169705617,"gmtCreate":1623850084139,"gmtModify":1631884324562,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"Hope it brings Starbucks to the next level of success!&nbsp;","listText":"Hope it brings Starbucks to the next level of success!&nbsp;","text":"Hope it brings Starbucks to the next level of success!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169705617","repostId":"2143763826","repostType":2,"isVote":1,"tweetType":1,"viewCount":350,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114487624,"gmtCreate":1623088687368,"gmtModify":1634037085172,"author":{"id":"3583321276956509","authorId":"3583321276956509","name":"vincetan","avatar":"https://static.tigerbbs.com/a2a0521052a18f232bf3b5240cd4ccb5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583321276956509","authorIdStr":"3583321276956509"},"themes":[],"htmlText":"We shall see!&nbsp;","listText":"We shall see!&nbsp;","text":"We shall see!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114487624","repostId":"1187003503","repostType":4,"repost":{"id":"1187003503","pubTimestamp":1623088169,"share":"https://www.laohu8.com/m/news/1187003503?lang=&edition=full","pubTime":"2021-06-08 01:49","market":"us","language":"en","title":"Apple announces iOS 15 for iPhones with lots of new social features","url":"https://stock-news.laohu8.com/highlight/detail?id=1187003503","media":"cnbc","summary":"Apple's Worldwide Developers Conference  is the company's annual showcase for its software. Apple reveals the latest version of iOS, its iPhone software, and updates to the software that runs on Apple TV, iPads, Apple Watch and Macs, in an effort to lure the best developers to sink time and investment into building software for Apple's computers.The bigger question is whether Apple will announce new hardware products. Often, it saves its best launches for the fall, around when new iPhones come o","content":"<div>\n<p>Apple's Worldwide Developers Conference (WWDC) is the company's annual showcase for its software. Apple reveals the latest version of iOS, its iPhone software, and updates to the software that runs on...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/apple-wwdc-live-updates-ios-15.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple announces iOS 15 for iPhones with lots of new social features</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple announces iOS 15 for iPhones with lots of new social features\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 01:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/07/apple-wwdc-live-updates-ios-15.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple's Worldwide Developers Conference (WWDC) is the company's annual showcase for its software. Apple reveals the latest version of iOS, its iPhone software, and updates to the software that runs on...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/apple-wwdc-live-updates-ios-15.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.cnbc.com/2021/06/07/apple-wwdc-live-updates-ios-15.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1187003503","content_text":"Apple's Worldwide Developers Conference (WWDC) is the company's annual showcase for its software. Apple reveals the latest version of iOS, its iPhone software, and updates to the software that runs on Apple TV, iPads, Apple Watch and Macs, in an effort to lure the best developers to sink time and investment into building software for Apple's computers.The bigger question is whether Apple will announce new hardware products. Often, it saves its best launches for the fall, around when new iPhones come out. This year, it released new Mac computers and iPads in the spring. But, sometimes it reveals new computers that run on the latest software. This year, some rumors have suggested it may introduce new MacBook Pro laptops and possibly an update to the AirPods headphones.We'll have everything Apple announces in the live blog below.The event begins at 1 p.m. Eastern.Is the iPad a computer yet?I can’t tell you how many WWDCs I’ve sat through where Apple claimed it’s beefed up the multitasking capabilities of the iPad in order to make it function more like a regular laptop.And Apple did it again today. (See Kif’s early blog entry for more details.)But none of those updates matter if app developers don’t take advantage of these features. Historically, it’s been difficult for Apple to convince developers to take the iPad seriously as a computer replacement, which is why the tablets are still mostly used for consumption, not creation.It’s way better than it used to be. (In fact, I use my iPad more than I use my MacBook these days.) But there’s still a long way to go for the iPad to catch up to the MacBook.There’s an easier solution though: Just put a touchscreen on the MacBook. Please.--Steve KovachApple announces new iPad software called iPadOS 15 that lets you do more at onceiPadOS Source: AppleApple announced new iPad software called iPadOS 15.IPadOS 15 includes new ways to rearrange iPad apps, put widgets on the home screen and the App Library feature, formerly iPhone exclusive, that automatically organizes apps.Apple also introduced a new multitasking interface that makes it easier to put two apps side by side on the iPad screen.The Apple notes app has been updated to better interface with other apps. One feature, called Quick Notes, lets users jot notes using the Apple Pencil, a stylus.A new version of the Translate app for iPads allows users to speak and have the discussion translated on-screen in real time.Apple’s app for learning how to code, Swift Playgrounds, can now build full apps, which can be submitted to the App Store Apple said.— Kif LeswingApple’s AirPods headphones can now be used to improve hearingA new feature coming to AirPods called “Conversation Boost” helps people better understand who they’re talking to in real time in a busy environment. Users can also adjust ambient background noise levels to help improve audio. Siri will also soon read important notifications, if you want it to, instead of just incoming calls and messages. — Kif LeswingApple Maps gets big new update with more city details and 3D modelsApple is updating its maps software with new 3D data. It now includes turning lanes and other road conditions. It is expanding to Spain, Portugal, Italy and Australia later this year, Apple said.— Kif LeswingIf you thought Facebook was angry with Apple before today...The slew of new communication features Apple announced for iOS 15 on Monday are sure to have Mark Zuckerberg’s blood boiling over atFacebookheadquarters.In effect, these new features build a closed-off social network for Apple, letting you share Apple News stories, Apple Music tracks and even hold FaceTime video chats with non-iPhone users.Zuckerberg has already said he considers Apple a major competitor because of iMessage. Now Apple is building out even more social features natively into iOS. And, of course, Apple will be able to promote the privacy of these social features, unlike Facebook.--Steve KovachApple announces iOS 15, newest version of iPhone’s softwareApple’s senior vice president in charge of software, Craig Federighi, announced iOS 15, the latest version of the iPhone operating system. This software typically releases for most users alongside new iPhones in the fall, but developers and early adopters can start using it earlier, typically during the summer.iOS 15 includes:FaceTime improvements, including 3D audio, portrait mode to blur backgrounds, and a grid view to speak to multiple people at the same time. Apple will also allow users to send links to schedule individual FaceTime calls, like Zoom links. Users can also share their screens or music, through a new software feature called ShareTime.FaceTime calls are also now supported on Windows and Android through a browser, the first time that FaceTime has been supported across platforms.An iMessage redesign, which includes features that turns messaged photos into galleries.A new feature called “shared with you” saves links that people sent you and puts them in one place so users can address them later. It works with Apple Music, Safari, Apple Podcasts, Apple TV and Apple News. Users can pin important messages featuring content.Redesigned notifications, including a feature that collects users notifications into a custom summary of all the notifications the user may have missed. The notifications are ordered by priority, and notifications by people will not be included so they won’t be missed.Users who have turned on “do not disturb” or a new “focus” mode will have their status shared with other users, like an away message.Focus mode can hide any apps that you don’t want to distract you.Camera improvements, including a feature called Live Text that can automatically identify and scan text in photographs.Apple’s machine learning will also be able to identify elements in photos, such as location or whether there’s a pet in the scene. Apple’s system search, Spotlight, will search these elements.A feature called Memories will use machine learning to combine photos into relevant galleries or animations and sometimes add music from Apple Music.Apple is also updating expanding the Wallet app functionality to include corporate badges as well as keys to get into hotels and houses with smart homes.Apple is also going to support scanning U.S. IDs, such as drivers licenses, into their wallet. Apple says it is only supported in some states for now, and the TSA will accept the credential.Apple CEO Tim Cook kicks off WWDCAfter a short comedy video focusing on software developers, Apple CEO Tim Cook has kicked off the show from the company’s headquarters in Cupertino, California. He came out on stage to a virtual crowd of avatars.— Kif LeswingFacebook CEO Mark Zuckerberg needles Apple ahead of its conferenceFacebook CEOMark Zuckerberg needled Applehours before its WWDC conference was scheduled to kick off.In a short poston his Facebook page, Zuckerberg announced a new Facebook feature enabling users to tip social media personalities. He said Facebook isn’t charging until at least 2023, and when it does, it will take less than the 30% fee Apple charges iPhone apps using in-app purchases.“To help more creators make a living on our platforms, we’re going to keep paid online events, fan subscriptions, badges, and our upcoming independent news products free for creators until 2023. And when we do introduce a revenue share, it will be less than the 30% that Apple and others take,” Zuckerberg wrote.Apple’s developer conference this year takes place at an uncertain time in Apple developer relations. Apple needs computer software companies to make apps for its platforms, which in turn makes its products more attractive to users.WWDC is aimed at getting those software makers excited about Apple. But Epic Games, Facebook and other firms have complained that Apple’s App Store rules are too stringent and its 30% fee for digital purchases is too high.— Kif LeswingApple’s web store remains onlineApple has historically taken down its online store for a few hours during a big launch, signaling exciting new products being added and building hype. But on Monday, the store was still up 15 minutes before WWDC was scheduled to kick off, suggesting no new major products.— Kif LeswingApple should bring Mac features to iPads todayI hope to see Apple bring some of the software features from MacBooks to iPads today.Thelatest MacsandiPad Pros run on the same M1 processor, so there’s enough power on the high-end iPads for running apps in multiple windows, like you would on a traditional computer, and support for using an external display for any app.A report fromBloombergover the weekend suggested we’ll at least see improvements to iPad multitasking, so it seems like my wish is at least plausible.Apple has so far said it sees iPads and Macs as totally different devices with different use cases, so I don’t expect a complete merge of the operating systems.-- Todd HaseltonThe Apple-developer love fest is overIn normal times, WWDC is a love fest between Apple and the developers who keep itsmassively profitable App Store chugging along.But this year is going to be different. The disputes over App Store fees between Apple and big-name developers likeSpotifyhave spilled into the public view in recent months. That’s especially apparent with thelegal battle between Apple and Epic Games. The two companies went through a three-week trial last month, and the judge’s decision in the case could alter the power dynamics between Apple and app developers.In the past, developers remained quiet about their complaints with Apple’s App Store rules, lest they draw the ire of Tim Cook and company and risk their access to the App Store. But thanks to groups like theCoalition for App Fairnessand the overall anti-Big Tech sentiment in Western governments, developers now feel emboldened to make their complaints known.I’m most interested to see how Apple uses this year’s WWDC to highlight the benefits it can offer developers while still protecting one of its massive profit centers, the App Store.-- Steve Kovach","news_type":1},"isVote":1,"tweetType":1,"viewCount":224,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}